

1 **Wastewater to clinical case (WC) ratio of COVID-19 identifies**
2 **insufficient clinical testing, onset of new variants of concern and**
3 **population immunity in urban communities**

4 Patrick M. D'Aoust^a, Xin Tian^a, Syeda Tasneem Towhid^a, Amy Xiao^g, Elisabeth Mercier^a,
5 Nada Hegazy^a, Jian-Jun Jia^a, Shen Wan^a, Md Pervez Kabir^a, Wanting Fang^a, Meghan Fuzzen^c,
6 Maria Hasing^f, Mingqing Ivy Yang^d, Jianxian Sun^e, Julio Plaza-Diaz^b, Zhihao Zhang^a, Aaron
7 Cowan^a, Walaa Eid^b, Sean Stephenson^b, Mark R. Servos^c, Matthew J. Wade^h, Alex E.
8 MacKenzie^b, Hui Peng^e, Elizabeth A. Edwards^d, Xiao-Li Pang^f, Eric J. Alm^g, Tyson E. Graber^b,
9 and Robert Delatolla^{a*}

10

11 a: Department of Civil Engineering, University of Ottawa, Ottawa, Canada

12 b: Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada

13 c: Department of Biology, University of Waterloo, Waterloo, Canada

14 d: Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto,
15 Canada

16 e: Department of Chemistry, University of Toronto, Toronto, Canada

17 f: Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada

18 g: Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge,
19 Massachusetts, United States of America

20 h: Data, Analytics and Surveillance Group, UK Health Security Agency, London, United
21 Kingdom

22

23 Corresponding author:

24 Dr. Robert Delatolla

1

25 Work E-mail: robert.delatolla@uOttawa.ca

26 **Abstract**

27 Clinical testing has been the cornerstone of public health monitoring and infection control
28 efforts in communities throughout the COVID-19 pandemic. With the extant and anticipated
29 reduction of clinical testing as the disease moves into an endemic state, SARS-CoV-2 wastewater
30 surveillance (WWS) is likely to have greater value as an important diagnostic tool to inform public
31 health. As the widespread adoption of WWS is relatively new at the scale employed for COVID-
32 19, interpretation of data, including the relationship to clinical cases, has yet to be standardized.
33 An in-depth analysis of the metrics derived from WWS is required for public health units/agencies
34 to interpret and utilize WWS-acquired data effectively and efficiently. In this study, the SARS-
35 CoV-2 wastewater signal to clinical cases (WC) ratio was investigated across seven different
36 cities in Canada over periods ranging from 8 to 21 months. Significant increases in the WC ratio
37 occurred when clinical testing eligibility was modified to appointment-only testing, identifying a
38 period of insufficient clinical testing in these communities. The WC ratio decreased significantly
39 during the emergence of the Alpha variant of concern (VOC) in a relatively non-immunized
40 community's wastewater (40-60% allelic proportion), while a more muted decrease in the WC
41 ratio signaled the emergence of the Delta VOC in a relatively well-immunized community's
42 wastewater (40-60% allelic proportion). Finally, a rapid and significant decrease in the WC ratio
43 signaled the emergence of the Omicron VOC, likely because of the variant's greater effectiveness
44 at evading immunity, leading to a significant number of new reported clinical cases, even when
45 vaccine-induced community immunity was high. The WC ratio, used as an additional monitoring
46 metric, complements clinical case counts and wastewater signals as individual metrics in its ability
47 to identify important epidemiological occurrences, adding value to WWS as a diagnostic
48 technology during the COVID-19 pandemic and likely for future pandemics.

49 **Keywords:** COVID-19; SARS-CoV-2; variant; wastewater-based epidemiology;
50 wastewater surveillance; public-health

51 **1 Introduction**

52 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had profound effects
53 around the world, claiming millions of lives and significantly impacting public health since its initial
54 identification in December 2019 (World Health Organization, 2021). The virus is an enveloped,
55 positive-sense RNA virus and, like other coronaviruses, predominantly causes respiratory and
56 intestinal tract infections (Chen et al., 2020; Xu et al., 2020; Zou et al., 2020). SARS-CoV-2
57 infections in humans can cause acute respiratory illness leading to elevated mortality and
58 morbidity rates (Challen et al., 2021; Fajnzylber et al., 2020; O'Driscoll et al., 2021). Early in the
59 COVID-19 pandemic, molecular diagnostic assays based on the reverse transcription quantitative
60 polymerase chain reaction (RT-qPCR) technology were rapidly developed (Zhu et al., 2020) and
61 became the principal testing method used to determine if patients were infected with COVID-19.
62 Other testing methodologies and technologies, such as rapid antigen testing and LAMP RT-PCR,
63 were also used globally. However, RT-qPCR testing remains the gold standard due to its
64 sensitivity and specificity, particularly at lower viral loads (Hirotsu et al., 2020; Uhteg et al., 2020).
65 Clinical testing in most jurisdictions around the world, including Canada, has predominantly
66 targeted symptomatic individuals (Long et al., 2020; Oran and Topol, 2020; Rivett et al., 2020).
67 The incubation period of SARS-CoV-2, together with the inherent lag associated with the RT-
68 qPCR clinical testing and reporting pipeline (typically measured in days) generates a significant
69 delay between infection incidence and the reporting of results, potentially delaying life-saving
70 public health actions. Wastewater surveillance (WWS) has emerged as an exemplary early
71 indicator of the incidence and disease burden of SARS-CoV-2 in the community (Al Huraimel et
72 al., 2020; Cao and Francis, 2021; Cavany et al., 2022; D'Aoust et al., 2021a). In the first year of
73 the pandemic, research on the pathogenicity of SARS-CoV-2 revealed that fecal shedding of viral
74 RNA is frequent, where approximately 30-90% of cases feature fecal shedding (Fontana et al.,

75 2020; Hua et al., 2020; Huang et al., 2020; Jones et al., 2020; Ling et al., 2020; Santos et al.,
76 2020). Thus, community-level measurements of the viral signal in wastewater are thought to act
77 as a proxy for community SARS-CoV-2 burden (Bibby et al., 2021a; D'Aoust et al., 2021a;
78 Karthikeyan et al., 2021; La Rosa et al., 2020; Olesen et al., 2021; Quilliam et al., 2020). In
79 addition, following wastewater-based viral signal over time provides near real-time information on
80 the virus dynamics such as incidence, prevalence, and disease burden (Ahmed et al., 2020;
81 Bivins et al., 2020; Chakraborty et al., 2021; D'Aoust et al., 2021b; Medema et al., 2020; Peccia
82 et al., 2020; Randazzo et al., 2020; Sherchan et al., 2020; Wu et al., 2020). Furthermore,
83 sequencing of wastewater or variant-specific RT-qPCR assays can also detect and track the
84 emergence/re-emergence of variants of interest/variants under investigation/variants of concern
85 (VOI/VUI/VOC) (Graber et al., 2021; Lee et al., 2021; Peterson et al., 2021; Yaniv et al., 2021).

86 With the growing amount of data available from multiple locations and COVID-19
87 resurgences, there now exists an opportunity to explore the relationships between clinical
88 reporting and WWS results to better understand and interpret patterns of both. With this data,
89 there is clear potential for hypothesis-driven approaches to identify mechanisms underlying
90 relationships between clinical testing patterns and observed SARS-CoV-2 viral signal in
91 wastewater within and between communities and facilities (Bibby et al., 2021b). It is hypothesized
92 that analyzing the change in the intrinsic relationship existing between clinical testing and
93 observed SARS-CoV-2 viral signal may reveal additional information regarding testing strategy
94 effectiveness in approximating true disease incidence in a community. Xiao *et al.* proposed a
95 metric to relate wastewater to epidemiological information; the wastewater to clinical (WC) ratio
96 (Xiao *et al.*, 2022). It was proposed by Xiao *et al.* (2022) that tracking and analyzing changes in
97 the WC ratio across time could yield additional information regarding clinical testing adequacy in
98 approximating true disease incidence, and perhaps ease of spread of a pathogen or its severity
99 in the community.

100 In this study, the WC ratio was analyzed over periods of 8 to 21 months in the seven
101 Canadian cities/regions of Ottawa, Kitchener, Toronto, Peel, Waterloo, Calgary, and Edmonton
102 to help identify if it could identify occurrences of major epidemiological importance during the
103 COVID-19 pandemic. The major epidemiological events were as follows: i) a period of insufficient
104 clinical testing during a change in clinical testing strategy (i.e., walk-in testing changed to
105 appointment-based testing); ii) the emergence of a more infectious VOC (Alpha) in the context of
106 low vaccine- or naturally-acquired community immunity; iii) the emergence of a more
107 transmissible and virulent VOC (Delta) in the context of high community immunity, and iv) the
108 emergence of a more transmissible VOC (Omicron) in the context of immunity escape in a
109 susceptible community. Furthermore, other possible confounding factors such as the age,
110 demographics, and vaccination rate of reported new clinical cases were also considered to assure
111 observed trends were not affected by these elements. The objective of this study was therefore
112 to investigate and quantify the ability of the WC ratio to identify major epidemiological occurrences
113 and further elucidate the relationship existing between WWS and reported clinical cases to
114 complement and enhance the value of WWS and its enhance its usefulness as an applied
115 diagnostic technology.

116 **2 Materials and methods**

117 Analytical testing completed in this study occurred in four different laboratories throughout
118 Canada, and as such specific methodologies, site-specific sampling schedules, sample
119 processing, extraction, and quantification techniques differ slightly between the various
120 cities/regions. Before starting, all employed methodologies were compared as part of a broader
121 pan-Canadian interlaboratory study (Chik et al., 2021) and determined to be of similar
122 performance under the tested conditions. A list of the testing periods included in this study and
123 the major epidemiological events identified at each testing site is shown below in Table 1.

124 Furthermore, a summary of the characteristics of each water resource recovery facility (WRRF)
 125 is shown in Supplementary Material (Table S1). The studied data sets for most locations stopped
 126 in August 2021, however, the studied data set in Ottawa (most frequently sampled and tested)
 127 was chosen to be extended into the Omicron VOC onset.

128 Table 1: Testing periods and analyzed major epidemiological events identified per studied site.

Location	Studied period	Identified change in clinical testing strategy changed to appointment based only	Identified onset of allelic proportionality of B.1.1.7 (Alpha) VOC reaching 40-60%	Identified onset of allelic proportionality of B.1.617.2 (Delta) VOC reaching 40-60%
Ottawa	06-04-2020 to 09-01-2022	06-10-2020	23-03-2021	31-07-2021
Toronto	11-02-2021 to 20-11-2021	-	02-03-2021	22-06-2021
Kitchener	01-12-2020 to 15-09-2021	-	10-03-2021	06-06-2021
Peel	20-09-2020 to 30-08-2021	06-10-2020	22-02-2021	28-05-2021
Waterloo	07-12-2020 to 15-09-2021	-	27-03-2021	14-06-2021
Edmonton	12-07-2020 to 26-09-2021	-	23-02-2021	18-07-2021
Calgary	09-07-2020 to 21-09-2021	-	22-03-2021	18-07-2021

129

130 2.1 Sample collection, enrichment, concentration, and extraction

131 Ottawa

132 24-hour composite samples of primary clarified sludge were collected from the City of
 133 Ottawa's sole WRRF, the Robert O. Pickard Environmental Centre (ROPEC), starting on Apr. 8th,
 134 2020, with daily sample collection beginning on Sep. 10th, 2020. The WRRF services
 135 approximately 91% of households and individuals in the City of Ottawa (pop.: 1.1M). Composites
 136 were collected every morning and kept on ice until transported to the University of Ottawa for
 137 analysis. In this study, samples were analyzed from Apr. 8th, 2020, until Jan. 5th, 2022. Primary

138 sludge samples were first homogenized well by mixing and then 40 mL of each sludge sample
139 was concentrated by centrifugation for 45 minutes at 10,000 x g. The supernatant was discarded
140 and the wet pellet was centrifuged a second time at 10,000 x g for an additional 5 minutes. The
141 resulting pellet was then homogenized, and 0.250 g \pm 0.05 g of the resulting solids pellet was
142 extracted as previously described using Qiagen's RNeasy PowerMicrobiome Kit (Qiagen,
143 Germantown, MD) using a QIAcube Connect automated extraction platform (D'Aoust et al.,
144 2021a, 2021b). RNA was finally eluted in 100 μ L of RNase-free water.

145 **Toronto**

146 24-hour composite samples of post-grit influent were collected from three water resource
147 recovery facilities in the City of Toronto, including Ashbridge's Bay (TAB), Highland Creek (THC),
148 and North Toronto (TNT) at frequencies of three to five times per week between Feb. 11th, 2021,
149 and Nov. 22nd, 2021. After arriving at the laboratory at the University of Toronto, two pseudo-
150 biological replicates (80 mL for TAB and THC samples, and 120 mL for TNT samples) were
151 centrifuged. The wastewater samples were then transferred to 50 mL centrifuge tubes in 40 mL
152 aliquots and centrifuged at 10,000 x g for 45 minutes at 4°C. After removal of the supernatant,
153 the remaining wet pellet was transferred to a 2 mL screw-cap microcentrifuge tube and further
154 centrifuged at 13,000 x g for 1 minute. After completely decanting the supernatant, the final pellet
155 and microcentrifuge tube was weighed. For pellets not exceeding 250 mg, RNA extraction was
156 performed as previously described using Qiagen's RNeasy PowerMicrobiome Kit (Qiagen,
157 Germantown, MD) (D'Aoust et al., 2021a, 2021b)., with the following modifications to the protocol:
158 10 μ L beta-mercaptoethanol and 100 μ L phenol:chloroform:isoamyl alcohol (25:24:1 v/v) mixtures
159 (Invitrogen, CAT# 15593031, USA) were added to the bead beating tube along with the lysis
160 buffer in the kit. For pellets exceeding 250 mg, each pellet was split into two portions to proceed
161 with cell lysis and inhibition removal (IRS), and only half of the combined supernatant from the

162 IRS step was used in the remaining extraction steps. Whole process controls were included for
163 each extraction. RNA was finally eluted in 100 μ L of RNase-free water.

164 **Kitchener, Peel, and Waterloo**

165 24-hour composite samples of post-grit influent were collected from the following locations:
166 (Kitchener) Region of Waterloo's water resource recovery facility (Dec. 7th, 2020, to Sep. 15th,
167 2021), (Peel) Clarkson water resource recovery facility (Aug. 8th, 2020, to Sep. 15th, 2021) and
168 G.E. Booth water resource recovery facility (Jul. 20th, 2020, to Aug. 30th, 2021), and (Waterloo)
169 Waterloo water resource recovery facility (Dec. 7th, 2020, to Sep. 15th, 2021). Samples were
170 collected at a frequency of three to five times per week. Samples were aliquoted into 250 mL
171 HPDE bottles (Systems Plus, Baden, Canada) and transported on ice to the University of
172 Waterloo. Upon arrival, the sample bottles were well mixed, and a 40 mL aliquot was poured into
173 50 mL centrifuge tubes containing 4 g PEG-8000 and 0.9 g NaCl and mixed on an orbital shaker
174 at 4°C for 2 h before being stored at 4°C overnight. The samples were then centrifuged at 12,000
175 x g at 4°C for 90 minutes with no deceleration/brake applied. The majority of the supernatant was
176 discarded, and the remaining sample was centrifuged again at 12,000 x g at 4°C for 5 minutes
177 with no deceleration/brake applied. The remaining supernatant was decanted/pipetted out and
178 the wet weight of the resulting pellet was recorded. Up to 250 mg of the pellet was used for RNA
179 extraction using the RNeasy PowerMicrobiome Kit (Qiagen, Germantown, MD) with the addition
180 of 100 μ L of TRIzol (Thermo Fisher, Ottawa, Canada) to the pellet before bead beating. RNA was
181 finally eluted in 100 μ L of RNase-free water.

182 **Edmonton and Calgary**

183 24-hour composite post-grit wastewater influent samples were collected from the following
184 locations: (Edmonton) EPCOR Gold Bar Wastewater Treatment (May 18th, 2020, to Sep. 26th,

185 2021) and the city of Calgary water resource recovery facility (May 17th, 2020, to Sep. 21st, 2021).
186 Samples were collected at a frequency of three to five times per week. Wastewater concentration
187 and RNA extraction were performed as previously described (Qiu et al., 2021). Briefly, 100 ml
188 wastewater samples were spiked with 100 µl of a suspension of human coronavirus (HCoV) strain
189 229E (10⁵ IU/ml titrated by TCID₅₀) to monitor virus recovery. The spiked samples were adjusted
190 to a pH of 9.6-10 using 5N NaOH, mixed vigorously for 30 seconds, and then centrifuged at 4,500
191 x g for 10 min to pellet solids. The liquid fraction was then transferred into a new container,
192 adjusted to pH 7-7.5 using 1.2N HCl, and then concentrated by ultrafiltration using a Centricon
193 Plus-70™ filter with a pore size or Nominal Molecular Weight Limit (NMWL) of 30 KDa (Merck
194 Millipore, Carrigtwohill, Ireland) at 3000 x g for 10 minutes at 4°C. The concentrated sample was
195 adjusted to a final volume of 1 ml by adding phosphate-buffered saline (PBS) and stored at -70°C
196 until RNA extraction. Viral RNA was extracted from ultrafiltration wastewater concentrates using
197 the MagMAX™-96 Viral RNA isolation kit (Thermo Fisher Scientific, Ottawa, Canada) and the
198 King Fisher™ Flex Purification System (Thermo Fisher Scientific, Ottawa, Canada) using 400 µl
199 of wastewater concentrate as input. RNA was finally eluted in 100 µL of elution buffer.

200 **2.2 RT-qPCR quantification of SARS-CoV-2, Pepper Mild Mottle Virus, Alpha,** 201 **Delta, and Omicron VOCs in wastewater**

202 Singleplex RT-qPCR quantification of SARS-CoV-2 targets and Pepper Mild Mottle Virus
203 (PMMoV) was performed in the four laboratories analyzing samples for this study. A summary of
204 the targeted SARS-CoV-2 genes, RT-qPCR reaction characteristics, and QA/QC controls utilized
205 in each laboratory during this study are shown below in Table 2. All probes and primers utilized
206 in this study are included in the Supplemental Material (Table S2). For viral signal normalization,
207 the copies of SARS-CoV-2 (N1/N2) detected per reaction were normalized against the quantified
208 copies of PMMoV from corresponding samples.

209
210

Table 2: Summary of the RT-qPCR quantification of SARS-CoV-2 targets and PMMoV in all four laboratories which performed analyses for this study.

	Ottawa	Toronto	Kitchener, Peel, and Waterloo	Edmonton and Calgary
Targeted SARS-CoV-2 regions	N1, N2, ND3L (Alpha), D63G (Delta), P13L (Omicron)	N1, N2, ND3L (Alpha), D63G/N200 (Delta)	N1, N2, ND3L (Alpha), D63G/N200 (Delta)	N1, N2, E, ND3L (Alpha), D63G (Delta)
Targeted biological normalizer	PMMoV	PMMoV	PMMoV	PMMoV
RNA template volume (µL)	3 (SARS-CoV-2 targets) / 1.5 (PMMoV)	4	5	5
Total RT-qPCR reaction volume (µL)	10	10	20	10
Supermix used	TaqMan™ 1-Step Fast Virus Master Mix (ABI)	TaqMan™ 1-Step Fast Virus Master Mix (ABI)	TaqPath™ 1-Step RT-qPCR Master Mix (ABI)	TaqMan™ 1-Step Fast Virus Master Mix (ABI)
Standard utilized	Exact Diagnostics SARS-CoV-2 RNA standard (COV019)	Custom concatenated plasmid containing N1, N2, and PMMoV gene regions	Exact Diagnostics SARS-CoV-2 RNA standard (COV019)	Custom in-vitro transcribed gblock
Standard curve points	5-6	5-6	5-6	5-6
Endogenous spike in	VSV	-	HCoV-229E, zebrafish dsDNA, MS2	-
Corrected for recovery efficiency?	No	No	No	No
Inhibition check?	Yes, via dilution	Yes, via dilution	Yes, via zebrafish dsDNA	Yes, via dilution
Assay limit of detection (ALOD) for N1, N2, PMMoV targets (copies/reaction)	3.2 (N1), 8.1 (N2), 7.6 (PMMoV)	1.6 (N1), 1.6 (N2)	-	1.6 (N1), 1.6 (N2)
RT-qPCR conditions	(All targets) Reverse trans.: 5 min. @ 50°C, 1 cycle Initial denat.: 20 sec. @ 95°C, 1 cycle Denaturation: 3 sec. @ 95°C, 45 cycles Anneal/ext.: 30 sec. @ 60°C, 45 cycles	(All targets) Reverse trans.: 5 min. @ 50°C, 1 cycle Initial denat.: 20 sec. @ 95°C, 1 cycle Denaturation: 3 sec. @ 95°C, 45 cycles Anneal/ext.: 30 sec. @ 60°C, 45 cycles	(N2, HCoV-229E, MS2) Reverse trans.: 15 min. @ 50°C, 1 cycle Initial denat.: 2 min. @ 95°C, 1 cycle Denaturation: 3 sec. @ 95°C, 45 cycles Anneal/ext.: 60 sec. @ 60°C, 45 cycles (N1, PMMoV) Reverse trans.: 15 min. @ 50°C, 1 cycle Initial denat.: 2 min. @ 95°C, 1 cycle Denaturation: 3 sec. @ 95°C, 45 cycles Anneal/ext.: 60 sec. @ 60°C, 45 cycles	(N1, N2, E and ND3L) Reverse trans.: 5 min. @ 50°C, 1 cycle Initial denat.: 20 sec. @ 95°C, 1 cycle Denaturation: 3 sec. @ 95°C, 45 cycles Anneal/ext.: 30 sec. @ 60°C, 45 cycles (D63G) Reverse trans.: 5 min. @ 50°C, 1 cycle Initial denat.: 20 sec. @ 95°C, 1 cycle Denaturation: 3 sec. @ 95°C, 45 cycles Anneal/ext.: 30 sec. @ 55°C, 45 cycles
Primer and probe concentrations	500 µM (primers) 125 µM (probes)	500 µM (primers) 125 µM (probes)	500 µM (primers) 125 µM (probes)	800 nM (primers) and 200 nM (probes) (N1, N2, E) 900 nM (primers) and 250 nM (probe) (ND3L) 800 nM (primers) and 250 nM (probes) (D63G)
Replicate exclusion threshold	Ct ≥ 0.5	Ct ≥ 0.5	Ct ≥ 0.5	None
Standard curve acceptance characteristics	R ² ≥ 0.95, 90% ≤ Eff. ≤ 120%	R ² ≥ 0.99, 95% ≤ Eff. ≤ 105%	R ² ≥ 0.95, 95% ≤ Eff. ≤ 105%	External standard curve characteristics (data from 10 separate RT-qPCR runs): R ² ≥ 0.99 95% ≤ Eff. ≤ 103% (N1 and N2) R ² ≥ 0.99 92% ≤ Eff. ≤ 113% (ND3L) R ² ≥ 0.99 90% ≤ Eff. ≤ 109% (D63G)
Other QA/QC performed	Extraction blank, no extrapolation of values, negative controls	Extraction blank, negative controls, positive controls	Extraction blank, no extrapolation of values, negative controls, positive controls, no RT controls	Extraction blank, negative controls. External standard curve was verified for each RT-qPCR run at two different standard dilutions; Ct values differences between standards in each run vs those from external standard curve should be within ± 1

211

212 **2.3 Epidemiological data**

213 Daily epidemiological data including new daily testing, reported positive COVID-19 cases,
214 and demographics of new infections were obtained throughout the study via Ottawa Public
215 Health's online portal (Ottawa Public Health, 2021), Public Health Ontario's COVID-19 online data
216 tool (Public Health Ontario, 2021), and the COVID-19 surveillance database of the Government
217 of Alberta (Government of Alberta, 2021). The epidemiological data were provided per
218 geographical area by the various public health units (known in certain jurisdictions as public health
219 agencies) to best match the watershed of each studied location. stratified by geographic areas
220 or sites having wastewater-based SARS-CoV-2 surveillance included in this study. Vaccination
221 information was obtained via Public Health Ontario's COVID-19 online data tool (Public Health
222 Ontario, 2021) for locations in Ontario, and from the Government of Canada's COVID-19
223 vaccination coverage information page (Government of Canada, 2021).

224 **2.4 Statistical analysis**

225 The Pearson's product-moment correlation coefficient (Pearson's r) was calculated to
226 evaluate the strength of the relationship between WWS-acquired, PMMoV normalized SARS-
227 CoV-2 viral signal and reported clinical cases throughout the study. Furthermore, to establish if
228 changes occurred in the WC ratio values during key epidemiological occurrences, the Mann-
229 Whitney U test was performed on the 15-day periods preceding and following the key
230 epidemiological occurrences. A non-parametric test (Mann-Whitney U test) was employed to
231 establish significance in changes of the WC ratio during key epidemiological occurrences to
232 remove distribution effects. A regression analysis and subsequent analysis of the residuals were
233 also performed between the 7-day midpoint average daily new reported clinical cases and the 7-
234 day midpoint average observed viral signal in wastewater to establish if any outliers existed.

235 **2.5 Calculation of the WC ratio**

236 The WC ratio in this study was calculated by using the PMMoV-normalized SARS-CoV-2
237 viral signal (N1-N2 average copies/copies PMMoV) and dividing this value by the number of
238 COVID-19 clinical cases on the same day, similar to what was described previously in the
239 literature (Xiao et al., 2022). No lead-lag correction was applied to the calculations of the WC ratio
240 (Cavany et al., 2022; D'Aoust et al., 2021a; Galani et al., 2022; Olesen et al., 2021).

241 **2.6 Calculation of VOC allelic proportions**

242 The allelic proportions of different SARS-CoV-2 VOCs were calculated by dividing
243 measured VOC-associated viral copies/g by the universal/non-mutated equivalent genomic
244 region viral copies/g, to obtain a percentage/proportion, as previously described (Graber et al.,
245 2021). This calculation allows to track what percentage of the viral signal observed in wastewater
246 is attributable to the presence of circulating VOCs.

247 **2.7 Standardization of SARS-CoV-2 measurements for comparison of curves**

248 The viral signal was first standardized to be of similar scale (on the same axis) by
249 multiplying the PMMoV-normalized viral signal measurements in Ottawa and Toronto by 100,000,
250 Kitchener by 300,000, Waterloo by 500,000, not modifying the measurement of Peel, and dividing
251 the measurements of Edmonton and Calgary by 1,000. This was performed to facilitate initial
252 comparison of results by community.

253 **3 Results and discussion**

254 **3.1 Overview of SARS-CoV-2 surveillance at studied sites**

255 Surveillance of SARS-CoV-2 viral signal at the studied sites began on different dates due
256 to the different laboratories employed to support WWS across the study cities. Ottawa samples
257 consisted of primary sludge, whereas samples for all other tested locations were post-grit influent
258 wastewater. This could potentially influence the PMMoV quantification and the corresponding
259 calculated WC ratio because of a higher weight-normalized concentration of PMMoV found in
260 solids issue primary sludge as compared to post-grit influent wastewater (data not shown).
261 Additionally, other factors such as the intra-day variations of laboratory measurements, the
262 inherent variations present due to the technology employed (PCR), and the various normalization
263 techniques (or lack thereof) may also impact reported results. The measured viral signals
264 (normalized with PMMoV for all locations in Ontario, non-normalized for locations in Alberta) are
265 shown to have a relatively good visual agreement with clinical data throughout the studied periods
266 (Figure 1a.). The COVID-19 pandemic in Canada has so far has been characterized by a surge
267 of COVID-19 cases in the early pre-vaccination stage of the pandemic (March 2020) followed by
268 four subsequent resurgences (Figure 1a.) in September 2020, December 2020, March 2021, and
269 December 2021. The scale-standardized viral signal observed in wastewater at all seven tested
270 sites demonstrates a good general agreement with the observed 7-day midpoint average for new
271 COVID-19 clinical cases reported by their respective public health units over the separate
272 resurgence periods, as determined via correlation analysis. A summary of the Pearson's r
273 correlation analyses is shown in the Supplementary Material (Table S3).

274 Mass immunization campaigns began in Canada in December 2020 for essential
275 healthcare workers and the most vulnerable in the community (elderly and the
276 immunocompromised). Vaccine rollout was relatively limited in early 2021, but vaccination rates
277 increased rapidly throughout spring and summer. Facemask mandates were present throughout
278 almost the entirety of the studied period, and intermittent gathering restrictions were also imposed
279 intermittently. All studied communities reached a full immunization rate of at least 60% by Sept.

280 1st, 2021, and a full immunization rate (two approved vaccine doses) of at least 70% by Nov. 1st,
281 2021 (Figure 2b.).




Figure 1: Comparison of a. scale-standardized PMMoV-normalized (Ottawa, Toronto, Kitchener, Peel and Waterloo) and non-PMMoV normalized (Edmonton and Calgary) SARS-CoV-2 viral signal measured in wastewater to reported new daily COVID-19 cases in the communities, with the onset of events of high epidemiological importance outlined with vertical dashed lines, coupled with b. summary of the immunization status of the populations living within the studied communities.

283 **3.2 The WC ratio as an indicator of key epidemiological occurrences in the cities**

284 One of the proposed methods to relate wastewater to epidemiological information is the
285 WC ratio, a ratio between wastewater viral titer and clinical cases was proposed by Xiao *et al.*
286 (2022). As the ratio has the wastewater titers in the numerator and the reported new clinical cases
287 in the denominator, Xiao *et al.* (2022) proposed that surveying the relative shifts in the WC ratio
288 may yield information regarding clinical testing. They also reported that an increased WC ratio
289 could be attributed to insufficient testing in the general population (i.e. testing not sufficient to
290 capture the exponential growth of actual COVID-19 cases). When performing this particular
291 analysis in all seven studied communities, significant changes in the WC ratio were hypothesized
292 as being indicative of four major events: 1) a change in the clinical testing strategy that introduced
293 the requirement to book a COVID-19 test appointment (5 out of 7 sites were in provinces that
294 invoked this testing strategy); 2) the onset of the B.1.1.7 VOC during periods of low community
295 immunity (all 7 sites were testing during this period), 3) the onset of the B.1.617.2 (Delta) VOC
296 during periods of high community immunity (all 7 sites were testing during this period), and 4) the
297 onset of the B.1.1.529 (Omicron) VOC during periods of high community immunization rates
298 (75%+), with a VOC which has demonstrated immunity escape (a single site was testing during
299 this period).

300 **3.3 Event #1: WC ratio as an indicator of change in clinical testing strategy**

301 Throughout the pandemic, public health units have adjusted their clinical testing strategies
302 to better track the rate of incidence and prevalence of SARS-CoV-2 in their communities and help
303 infer additional information, such as an approximate number of active disease cases and the
304 pathogen's reproduction rate (China Center for Disease Control, 2020; Hoseinpour Dehkordi *et al.*
305 *et al.*, 2020; Hyafil and Moriña, 2020; Khailaie *et al.*, 2021; Kolifarhood *et al.*, 2020; Pan *et al.*, 2020).

306 PCR-based clinical testing methods have been the primary metric of COVID-19 rates of incidence
307 and prevalence in communities for public health professionals. However, RT-PCR nucleic acid
308 clinical tests are not without limitations; first, individuals may decline clinical testing or refuse to
309 seek medical treatment during a pandemic despite being symptomatic, complicating both tracking
310 of cases and contact tracing (Novoa et al., 2021), and second, RT-PCR test results may suffer
311 from a substantial false-negative rate, especially when considering the time of testing in relation
312 to symptom onset and the type of sample collected (sputum, stool, nasopharyngeal,
313 oropharyngeal, etc.) (da Rocha Araujo, 2020; Hatchette, 2009; Wikramaratna et al., 2020).

314 An epidemiologically important event occurred when changes in clinical testing strategies
315 were effected in the province of Ontario (affecting Ottawa, Kitchener, Toronto, Peel and Waterloo),
316 Canada on October 6th, 2020. In response to an increasing backlog of tests, and to ensure
317 individuals could get tested at a specific time with minimal wait (Crawley et al., 2020), provincial
318 guidelines and the framework for the initiation of SARS-CoV-2 RT-PCR clinical testing were
319 changed from an open-access, walk-in format to one in which individuals were required to book
320 an appointment before testing. This change in testing strategy presented a significant, if brief,
321 barrier for Ontario residents wanting to be tested for COVID-19 by necessitating online bookings,
322 which made it more difficult for groups of the general population to access testing resources.
323 WWS had already been introduced in Ottawa and Peel during this period and, as such, a
324 quantitative analysis of the effects of changes in testing strategies was performed.

325 When comparing the preceding 15-day period (Sept. 21st, 2020 – Oct. 5th, 2020) before
326 the testing strategy change and the next 15-day period after enactment of the change (Oct. 6th,
327 2020 – Oct. 21st, 2020) in Ottawa the number of clinical tests performed on the general population
328 decreased by an average of 23.2% (Figure 3a.). Concurrently, the local public health units
329 reported a corresponding decrease of 16.8% in detected new clinical cases of COVID-19 in

330 Ottawa and an increase of 22.1% in Peel (Figure a. and 3b.). During the same period, Ottawa's
331 normalized viral signal (average of N1-N2 viral copies/copies PMMoV) reported an increase of
332 55.9%, and the corresponding WC ratio increased by over 189% (Figure a.). Meanwhile, in Peel,
333 the normalized viral signal increased by 19.7% increase while the WC ratio increased by only
334 7.5%. The important increase in WC ratio in Ottawa occurred due to both increased wastewater
335 signal and decreasing numbers of reported new clinical cases occurring simultaneously, thereby
336 amplifying the increase in the WC ratio. The weak increase in the WC ratio observed in Peel is
337 hypothesized to have been caused by less frequent wastewater testing before and after the
338 change in the testing strategy. The WWS program in Peel during this period was very close to
339 inception and sampling was not as frequent before and after the change in the clinical testing
340 strategy. During this period, variant testing in Ottawa's wastewater confirmed that no known major
341 VOC was circulating in the general population, and an analysis of the age demographic of new
342 cases (Figure S1) showed no statistically significant difference during the 30-day sample set.
343 Based on the observed rapid increase (>50%) in the WC ratio observed in Ottawa, it is
344 hypothesized that the WC ratio may be an indicator of issues, such as flawed or difficult to access
345 clinical testing resources, or overall insufficient clinical testing in relation to wastewater viral signal.
346 This agrees with the findings and observations presented by Xiao *et al.* (2022).

347 While clinical testing currently remains the frontline measure of choice for the surveillance
348 and tracking of COVID-19 incidence in the community, these findings strongly suggest that current
349 and future disease surveillance efforts will benefit immensely from a multi-pronged surveillance
350 approach incorporating more than the potentially biased case rates of clinically acquired diseases.
351 COVID-19 and pandemic-potential diseases have been difficult to accurately track using
352 traditional clinical testing methods as they are generally less effective at surveying disease burden
353 due to many contributing factors, including testing capacity, the ability, and the desire of
354 individuals to be tested (Gonsalves and Yamey, 2020; Jaiswal *et al.*, 2020; Malinverni and




Figure 3: Comparison of the number of daily SARS-CoV-2 RT-PCR nucleic acid clinical tests performed and corresponding daily new COVID-19 positive cases, the daily viral signal measured through a SARS-CoV-2 wastewater surveillance program and the corresponding wastewater/clinical cases ratio (WC) during the same period, in a. Ottawa, and b. Peel.

355 Brigagão, 2020; Uscinski et al., 2020). It will continue to be difficult to conduct the widespread,
 356 mandatory disease surveillance of a population that is necessary to obtain information that could
 357 be interpreted as fully random and representative of the true rate of incidence of disease
 358 (McDermott and Newman, 2020; Pouwels et al., 2021; Rubin, 2020; Shao et al., 2020). In this
 359 context, it is therefore highly useful to utilize WWS and the WC ratio to complement traditional
 360 clinical testing results. WWS and the resulting measured viral load can be used as a confirmatory
 361 measure of actual rates of disease burden in the community, while rapid changes in the WC ratio
 362 may help identify periods of inadequate or altered clinical testing. Specifically, observing changes
 363 in the relative WC ratio may allow for the detection of changes in reported clinical cases that are
 364 not linked to actual changes in viral load in the community but are instead linked to shifts in testing
 365 rules and regulations, testing strategies, or fundamental changes in the disease vector. It is

366 however important to also consider potential variations and uncertainties present in WWS (Ahmed
367 et al., 2022; Li et al., 2021; Wade et al., 2022), as these will also have an impact on the WC ratio.
368 It is hypothesized that in this study, due to trends observed during the change in testing strategies,
369 is it likely that reported clinical cases may have been underreported in Ottawa and to a lesser
370 extent, Peel, following the modification to the testing strategies applied in these communities. To
371 determine the statistical significance of the change in WC ratio in both Ottawa and Peel during
372 the studied periods, a non-parametric Mann-Whitney U test was performed, and the
373 corresponding p-value was calculated. In Ottawa, the WC ratio before the change in strategy had
374 a mean of 4.8×10^{-6} (IQR = 2.8×10^{-6} - 6.1×10^{-6}), while the mean after the change in testing
375 strategy was 1.4×10^{-5} (IQR = 8.2×10^{-6} - 1.4×10^{-5}). As hypothesized, changes in the testing
376 strategy correlated with an increase in WC ratio (p-value < 9×10^{-5}). In Peel, the WC ratio before
377 the change in testing strategy had a mean of 0.23 (IQR = 0.17 - 0.28), while the WC ratio after
378 the change in testing strategy had a mean of 0.24 (IQR = 0.18 - 0.27). Change of the testing
379 strategy in Peel did not appear to have a quantifiable effect on the WC ratio (p=0.886), however
380 testing frequency was low during this period, which may explain the non-conclusive result.

381 **3.3.1 Event #2: WC ratio as an indicator of the onset of the B.1.1.7 (Alpha) variant of**
382 **concern**

383 SARS-CoV-2, being an RNA virus, is susceptible to mutations that can cause changes in
384 its epidemiological characteristics, such as increased infectivity and/or virulence in comparison to
385 its ancestral lineages (Burki, 2021; Drake and Holland, 1999; Duffy, 2018; Holmes and Rambaut,
386 2004). Throughout the COVID-19 pandemic, mutations of the SARS-CoV-2 spike (S) protein,
387 referred to colloquially as D614G and N501Y, became hallmarks of the B.1.1.7 VOC, now referred
388 to as the Alpha VOC. The onset of the Alpha VOC resulted in increased transmission of COVID-
389 19 in the community (Frampton et al., 2021; Galloway et al., 2021; Graham et al., 2021),
390 potentially affecting both observed viral load via WWS and new daily reported COVID-19 cases
391 in the community by the public health unit. The period of onset of the Alpha VOC in the seven
392 studied communities was confirmed via RT-qPCR allelic proportion determination (Figure 4) using
393 a previously developed and validated assay (Graber et al., 2021). The onset of the Alpha VOC in
394 a community was defined as such by determining when a consistent B.1.1.7 VOC allelic
395 proportionality of between 40-60% of the SARS-CoV-2 viral signal in wastewater was reached
396 and subsequently exceeded.

397 Using Ottawa as an initial test case, when comparing the average of the preceding 15-day
398 period and the average of the next 15-day period after the period of onset of the B.1.1.7 VOC, the
399 number of clinical tests performed on the general population increased by 19.6% (Figure 4a.) and
400 the local public health team reported a corresponding increase of 188.3% in the detection new
401 daily clinical cases of COVID-19 (Figure 4b.). During the same period, normalized WWS reported
402 a more modest increase of 70.8% in measured viral signal (average of N1-N2 viral copies/copies
403 PMMoV). Furthermore, the WC ratio decreased by 56.3% (Figure 4c.). An analysis of the age
404 demographic of new cases and changes in community immunization (Figure S2) showed no

405 statistically significant difference during the studied 30-day period. The percentage of the total
 406 population fully immunized (2 doses +) increased from 2% to 2.3% during the studied 30-day
 407 period, but due to the time required for immuno-competence development and overall very low
 408 immunization rate, it is understood that vaccination was not likely to be an important factor in
 409 affecting reported clinical cases or viral fecal shedding dynamics during this period (Public Health
 410 Ontario, 2021).




Figure 4: Comparison of a. the number of daily SARS-CoV-2 RT-PCR nucleic acid clinical tests performed and corresponding daily new COVID-19 positive cases in Ottawa, Canada, b. the daily viral signal measured through a SARS-CoV-2 wastewater surveillance program servicing approx. 91% of the City of Ottawa's population (pop.: 1.1M) and c. the corresponding wastewater/clinical cases ratio (WC) during the same period, overlaid with the progression of the allelic expression of the B.1.1.7 (Alpha) VOC in wastewater.

411 A summary of proportional observed changes in the preceding 15-day period and following
412 15-day period in reported clinical cases of COVID-19, measured viral signal in wastewater and
413 WC ratio at all seven tested locations is shown in the Supplementary Material (Table S4).
414 Individually, proportional changes in reported clinical cases and measured SARS-CoV-2 viral
415 signal in wastewater varied, however, in six of seven tested locations during this period, a marked
416 decrease in the observed WC ratio (average decrease of 41.6%) was observed, signaling the
417 emergence of the B.1.1.7 VOC as the dominant source of new infections (Figure 5). Only in
418 Calgary did the WC ratio increase (6.4%) during the onset of the B.1.1.7 VOC. This trend in the
419 decrease of the WC ratio signaling important changes in disease dynamics is consistent with
420 observations by Xiao et al. (2022) for the Boston area during the period where the Alpha VOC
421 became dominant in wastewater (Lee et al., 2021). The onset of the Alpha VOC led to an
422 observed change in the relationship between the number of reported COVID-19 cases and the
423 observed WWS viral signal, and its hypothesized that the Alpha VOC may have altered viral fecal
424 shedding dynamics in terms of viral load in fecal matter over time (Miura et al., 2021). It has been
425 suggested in the literature that there may be increased viral loading in symptomatic individuals
426 caused by the Alpha variant as compared to the wild type of SARS-CoV-2 based on data obtained
427 from nonhuman primates (Rosenke et al., 2021). However, there is not yet a consensus on this
428 matter for human subjects (Badu et al., 2021; Zhu et al., 2021). The decrease in the WC ratio
429 could also have been caused by a greater increase in transmissibility of the disease without a
430 corresponding increase in fecal shedding (unequal variance in viral load in tissue and secretions),
431 increased awareness in the general population, or increased severity of symptoms thereby

432 leading more infected individuals to seek clinical testing, resulting into a lower WC ratio after the
 433 onset.




Figure 5: Comparison of the WC ratio and B.1.1.7 allelic proportionality during the onset of the B.1.1.7 (Alpha) VOC in the additional 6 locations in Canada (Toronto, Kitchener, Peel, Waterloo, Edmonton, and Calgary).

434 Mann-Whitney U tests were performed on each data set during the Alpha VOC onset to
 435 investigate the shifts in WC ratios in the studied locations. The results of the tests, along with
 436 accompanying interpretation, are shown below in Table 3.

437 Table 3: Mean WC ratio and interquartile ranges (1st and 3rd quartiles) before and after the Alpha VOC onset along
 438 with the results of Mann-Whitney U tests performed on the WC ratio data sets to evaluate the significance of shifts
 439 before and after the Alpha VOC onset. The resulting p-value, and textual interpretation are also shown to establish if
 440 the WC ratio shift was statistically significant.

Location	Mean WC ratio (before)/(after)	IQR (1 st / 3 rd quartiles)	Mann-Whitney U test p-value	Interpretation
Ottawa	1.4×10^{-5} / 6.3×10^{-6}	$4.5 \times 10^{-6} - 2.4 \times 10^{-5}$ / $4.1 \times 10^{-6} - 8.5 \times 10^{-6}$	0.254	As hypothesized, decreases in the WC ratio occurred during the Alpha onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$).
Toronto	2.9×10^{-6} / 2.1×10^{-6}	$2.4 \times 10^{-6} - 3.6 \times 10^{-6}$ / $1.7 \times 10^{-6} - 2.7 \times 10^{-6}$	0.165	As hypothesized, decreases in the WC ratio occurred during the Alpha onset however the Mann Whitney U test could

				not establish statistical significance ($p < 0.1$). Lower frequency of testing could have had an impact on the test results.
Kitchener	$4.7 \times 10^{-6} / 2.9 \times 10^{-6}$	$1.6 \times 10^{-6} - 6.3 \times 10^{-6} / 2.1 \times 10^{-6} - 3.5 \times 10^{-6}$	0.886	As hypothesized, decreases in the WC ratio occurred during the Alpha onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$). Lower frequency of testing could have had an impact on the test results.
Peel	0.29 / 0.14	0.21 – 0.37 / 0.10 – 0.16	0.886	As hypothesized, decreases in the WC ratio occurred during the Alpha onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$). Lower frequency of testing could have had an impact on the test results.
Waterloo	$3.6 \times 10^{-6} / 2.4 \times 10^{-6}$	$2.0 \times 10^{-6} - 3.7 \times 10^{-6} / 1.6 \times 10^{-6} - 2.9 \times 10^{-6}$	0.223	As hypothesized, decreases in the WC ratio occurred during the Alpha onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$). Lower frequency of testing could have had an impact on the test results.
Edmonton	$1.8 \times 10^2 / 1.5 \times 10^2$	$1.1 \times 10^2 - 2.1 \times 10^2 / 1.9 \times 10^2 - 3.0 \times 10^2$	0.347	As hypothesized, decreases in the WC ratio occurred during the Alpha onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$). Lower frequency of testing or lack of normalization for flow/dilution effects could have had an impact on the test results.
Calgary	$3.2 \times 10^2 / 3.4 \times 10^2$	$1.1 \times 10^2 - 2.1 \times 10^2 / 1.9 \times 10^2 - 3.0 \times 10^2$	0.391	Contrary to hypothesized, increases in the WC ratio occurred during the Alpha onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$). Lower frequency of testing or lack of normalization for flow/dilution effects could have had an impact on the test results.

441

442 **3.3.2 Event #3: WC ratio as an indicator of the onset of the B.1.617.2 (Delta) variant of**
443 **concern**

444 Mutations in the SARS-CoV-2 genome at the N-terminal domain (NTD) and receptor-
445 binding domain (RBD) locations led to the rise of the B.1.617 lineage first identified in October
446 2020 in India (Cherian et al., 2021; Yadav et al., 2021), culminating in the dominance of the Delta
447 variant (B.1.617.2) in new COVID-19 infections in most locations in North America, including
448 Canada. The Delta variant is characterized by increased transmissibility and virulence compared
449 to the Alpha variant (Kannan et al., 2021; Liu et al., 2021; Planas et al., 2021). The periods of
450 onset of the Delta VOC in the four studied communities with available data (Ottawa, Kitchener,
451 Peel, and Waterloo) were confirmed via RT-qPCR allelic proportion determination of the D63G
452 portion of the genome using an assay developed and validated in-house. These periods of onset
453 were defined as reaching a B.1.617.2 VOC allelic proportion of 40-60% of the SARS-CoV-2 viral
454 signal in wastewater and subsequently exceeding this proportionality.

455 Using Ottawa as an initial test case, when comparing the average of the preceding 15-day
456 period and the average of the next 15-day period after the onset of the B.1.617.2 VOC a modest
457 increase (14.0%) in clinical tests that were performed was observed (Figure 6a.). Meanwhile,
458 during the same period, the reported new clinical cases of COVID-19 more than doubled,
459 increasing by 121.1%. This trend was similar to what was observed during the onset of the Alpha
460 variant for both the number of clinical tests performed and new daily COVID-19 cases in Ottawa.
461 However, the total numbers of new reported COVID-19 cases per day were substantially lower
462 by approximately one order of magnitude during the onset of the Delta variant. Specifically, a 15-
463 day average of 9.1 new cases per day was observed during the onset of the Delta variant, while
464 the 15-day average was 117.3 new cases per day during Alpha variant onset. These differences
465 in observed new COVID-19 cases in the community were likely driven by immunization effects;

466 as of Mar. 23th, 2021 (onset of Alpha variant), only 2.2% of the population in Ottawa was fully
467 immunized, compared to 63.1% in Jul. 31st, 2021 (onset of the Delta variant) (Public Health
468 Ontario, 2021). During the same period, the normalized WWS signal increased by 45.8%
469 (average of N1-N2 viral copies/copies PMMoV), which is similar to the trend observed during the
470 onset of the Alpha variant (44.5% increase). These combined factors led to a slight decrease of
471 only 18.7% in the WC ratio during the onset of the Delta variant, compared to a significantly larger
472 decrease of 56.3% during the Alpha variant onset. An analysis of the age demographic of new
473 cases and changes in community immunization (Figure S3) showed no statistically significant
474 difference during the studied 30-day period. It is hypothesized that immunization impact
475 dampened both increases in reported new COVID-19 cases and viral signal in wastewater,
476 effectively dampening the expected effects of the onset of a new, more infectious variant of SARS-
477 CoV-2 on the WC ratio. Accordingly, communities with lower rates of immunization could be
478 expected to exhibit greater reductions of the WC ratio due to increased rates of infections resulting
479 in higher numbers of new daily COVID-19 cases. During the 30-day period where Delta emerged
480 in Ottawa, full immunization in the total population (2 doses +) increased from 54.2% on Jul. 16th,
481 2021, to 66.9% on Aug. 14th, 2021), which likely limited the spread of the Delta variant within the
482 community during this time, as attested by the observed viral load in wastewater and reported
483 clinical cases (Figure 2a.).

484




Figure 6: Comparison of a. the number of daily SARS-CoV-2 RT-PCR nucleic acid clinical tests performed and corresponding daily new COVID-19 positive cases in Ottawa, Canada, b. the daily viral signal measured through a SARS-CoV-2 wastewater surveillance program servicing approx. 91% of the City of Ottawa's population (pop.: 1.1M) and c. the corresponding wastewater/clinical cases ratio (WC) during the same period, overlaid with the corresponding progression of the allelic expression of the B.1.617.2 (Delta) VOC in wastewater.

485 A summary of proportional observed changes in the preceding 15-day period and following
 486 15-day period in reported clinical cases of COVID-19, measured viral signal in wastewater, and
 487 WC ratio at the tested locations is shown in the Supplementary Material (Table S4). Individually,
 488 proportional changes in reported clinical cases and measured SARS-CoV-2 viral signal in
 489 wastewater varied, however in three of the five tested locations (Ottawa, Toronto and Waterloo),
 490 the WC ratio decreased by an average of 27.0% during the emergence of the B.1.617.2 VOC as
 491 the dominant source of new infections. Meanwhile, in the four other tested locations with data
 492 during the emergence of the B.1.617.2 VOC (Peel, Kitchener, Edmonton and Calgary), the WC
 493 ratio instead increased by an average of 53.8%. A visual comparison of the WC ratio changes
 494 during the onset of the B.1.617.2 VOC is shown below in Figure . Contrary to trends observed
 495 during the B.1.1.7 VOC, the overwhelming trend in the WC ratio was not a decrease. It is believed
 496 that this increase in WC ratio in some of the locations (Peel, Kitchener, Edmonton and Calgary)
 497 may have been indicative of a disconnect between reported clinical cases in the communities and
 498 observed viral signal, caused partly by community immunization (hypothesized to lead to lower




Figure 7: Comparison of the WC ratio and B.1.617.2 allelic proportionality during the onset of the B.1.617.2 (Delta) VOC in 6 additional locations in Canada (Toronto, Kitchener, Peel, Waterloo, Edmonton, and Calgary).

499 viral loads in feces) and local clinical testing capacity being reached or exceeded, leading to
 500 elevated WC ratio values caused by artificially low reported clinical cases. It is likely that in
 501 immunized communities without VOCs capable of immune escape, the change in the observed
 502 WC ratio will be lessened. Under such circumstances, the WC ratio is less indicative of the onset
 503 of new VOCs entering the community. Mann-Whitney U tests were performed on each data set
 504 during the Delta VOC onset to investigate the shifts in WC ratios in the studied locations. The
 505 results of the tests, along with accompanying interpretation, are shown below in Table 4.

506 Table 4: Mean WC ratio and interquartile ranges (1st and 3rd quartiles) before and after the Delta VOC onset along
 507 with the results of Mann-Whitney U tests performed on the WC ratio data sets to evaluate the significance of shifts
 508 before and after the Delta VOC onset. The resulting p-value, and textual interpretation are also shown to establish if
 509 the WC ratio shift was statistically significant.

Location	Mean WC ratio (before)/(after)	IQR (1 st / 3 rd quartiles)	Mann-Whitney U test p-value	Interpretation
Ottawa	4.6×10^{-5} / 3.8×10^{-5}	$2.5 \times 10^{-5} - 6.4 \times 10^{-5}$ / $1.5 \times 10^{-5} - 4.3 \times 10^{-5}$	0.079	As hypothesized, decreases in the WC ratio occurred during the Delta onset, and the Mann Whitney U test could establish statistical significance ($p < 0.1$).
Toronto	6.0×10^{-6} / 3.5×10^{-6}	$3.0 \times 10^{-6} - 6.4 \times 10^{-6}$ / $2.1 \times 10^{-6} - 3.5 \times 10^{-6}$	0.132	As hypothesized, decreases in the WC ratio occurred during the Delta onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$).
Kitchener	1.2×10^{-5} / 9.9×10^{-6}	$8.1 \times 10^{-6} - 1.8 \times 10^{-5}$ / $7.3 \times 10^{-6} - 1.1 \times 10^{-5}$	0.409	As hypothesized, decreases in the WC ratio occurred during the Delta onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$). Lower frequency of testing could have had an impact on the test results.
Peel	0.26 / 0.28	0.16 – 0.32 / 0.24 – 0.45	0.257	Contrary to the emitted hypothesis, increases in the WC ratio occurred during the Delta onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$). Lower frequency of testing could have had an impact on the test results.
Waterloo	2.7×10^{-5} / 3.8×10^{-5}	$6.1 \times 10^{-6} - 2.7 \times 10^{-5}$ / $2.2 \times 10^{-5} - 6.1 \times 10^{-5}$	0.065	Contrary to the emitted hypothesis, increases in the WC ratio occurred during the Delta onset, and the Mann Whitney U test established statistical

				significance ($p < 0.1$). Lower frequency of testing could have had an impact on the test results.
Edmonton	$5.4 \times 10^2 / 6.0 \times 10^2$	$4.1 \times 10^2 - 8.4 \times 10^2 / 2.6 \times 10^2 - 9.0 \times 10^2$	0.201	Contrary to hypothesized, increases in the WC ratio occurred during the Delta onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$). Lower frequency of testing or lack of normalization for flow/dilution effects could have had an impact on the test results.
Calgary	$4.7 \times 10^2 / 1.5 \times 10^3$	$3.5 \times 10^2 - 5.8 \times 10^2 / 7.5 \times 10^2 - 1.1 \times 10^3$	0.624	Contrary to hypothesized, increases in the WC ratio occurred during the Delta onset, however the Mann Whitney U test could not establish statistical significance ($p < 0.1$). Lower frequency of testing or lack of normalization for flow/dilution effects could have had an impact on the test results.

510

511 **3.3.3 Event #4: WC ratio as an indicator of the onset of the B.1.1.529 (Omicron) variant of**
 512 **concern**

513 Later in the pandemic, further mutations on the S protein RBD locations resulted in a very
 514 genotypically different VOC, denoted B.1.1.529 (Omicron). The combination of several mutations
 515 observed previously in the C.37 (Lambda) variant and several new mutations on the S protein
 516 RBD resulted in a significantly more infectious yet symptomatically milder VOC (Halfmann et al.,
 517 2022; Shuai et al., 2022), which spread rapidly around the world and replacing Delta as the main
 518 VOC in the majority of the location where it established. One of the important characteristics of
 519 Omicron is its ability to potentially evade neutralization in sera, even in vaccine-immunized
 520 individuals (He et al., 2021; Zhang et al., 2021).

521 Using Ottawa as an initial test case, when comparing the average of the preceding 15-day
 522 period and the average of the next 15-day period after the period of onset of the B.1.1.529 VOC
 523 (December 20th, 2021), the number of clinical tests performed on the general population increased

524 by 29.6% and the local public health reported a corresponding increase of 497.3% in the detection
525 new clinical cases of COVID-19 (Figure 8a.). During the same period, normalized WWS reported
526 an important increase of 243.5% in measured viral signal (average of N1-N2 viral copies/copies
527 PMMoV). At the same time, the WC ratio decreased by 41.9% (Figure 8c.). It is believed that
528 significant decreases in the WC ratio are an indicator of the onset of new VOCs with immune
529 escape abilities. An analysis of the age demographic of new cases and changes in community
530 immunization (Figure S4) showed no statistically significant difference during the studied 30-day
531 period. Daily vaccination rates during the studied 30-day period increased slightly over time due




Figure 8: Comparison of a. the number of daily SARS-CoV-2 RT-PCR nucleic acid clinical tests performed and corresponding daily new COVID-19 positive cases in Ottawa, Canada, b. the daily viral signal measured through a SARS-CoV-2 wastewater surveillance program servicing approx. 91% of the City of Ottawa's population (pop.: 1.1M) and c. the corresponding wastewater/clinical cases ratio (WC) during the same period, overlaid with the corresponding progression of the allelic expression of the B.1.1.529 (Omicron) VOC in wastewater.

532 to residents obtaining third-dose booster vaccinations, but due to the time required for immuno-
 533 competence development, it is understood that vaccination was not likely to be a major factor
 534 influencing changes of the WC ratio.

535 3.4 Discussion

536 The in-depth analysis of the WC ratio during several major epidemiological events (as
537 described in the above sections) revealed several major trends and findings: First, performed
538 alone, both traditional clinical testing and WWS sometimes provide limited information for public
539 health units that are monitoring a major pandemic disease like COVID-19. Clinical testing appears
540 to sometimes suffer from underreporting due to the limited reach of the clinical tests, coupled with
541 the limits in the ability and the desire of individuals to be tested, especially if they do not feel
542 unhealthy. Furthermore, a strong relationship exists between the number of clinical tests
543 performed and the number of detected new cases in the community, particularly during periods
544 of disease resurgence, where a high degree of community transmission occurs, potentially biasing
545 interpretations of results. It is hypothesized that this weakness in traditional clinical testing is due
546 to the difficulty in performing enough tests throughout the community to constitute testing rates
547 that approximate a random distribution. In contrast, WWS effectively tests all individuals
548 connected to the sewershed regardless of whether they are symptomatic or believe they have
549 been exposed to the virus. Monitoring the WC ratio while performing RT-qPCR-based WWS can
550 accurately detect the time of arrival of new variants of concern in a community during a pandemic
551 as quickly as traditional clinical testing and does not require infected individuals to seek clinical
552 testing or enter the healthcare system. Throughout the study, it appears that a shift in the rate of
553 change of the WC ratio (slowing of a decreasing trend) and the relationship between reported
554 clinical cases and observed WWS signal occurred for three reasons: (i) immunization may
555 significantly reduce the number of individuals seeking COVID-19 testing due to a reduction of
556 apparent symptoms caused by vaccination; (ii) as the pandemic progresses, disinterest may
557 develop in the population, leading to a lower likelihood of symptomatic individuals seeking clinical
558 testing, particularly if they have been immunized; and (iii) immunization may affect individual fecal
559 shedding characteristics, impacting observed viral signal in wastewater. However, at present, it

560 is still uncertain if this is the case, although preliminary results and unpublished data suggest this
561 trend may exist (Bivins and Bibby, 2021).

562 Finally, during the onset of the highly infectious and immunity evading Omicron variant,
563 very strong increases in reported clinical cases and observed viral signal in wastewater co-
564 occurred with a strong decrease in the WC ratio. It is hypothesized that the magnitude of change
565 in the WC ratio in a longitudinal analysis of a single testing location may correlate with the overall
566 disease burden in the community (Figure 9). At points of inflection in the WC ratio, caused by




Figure 9: Comparison of WC ratio amplitude during the 30-day periods of onset of the B.1.1.7 (Alpha), B.1.617.2 (Delta) and B.1.1.529 (Omicron) VOCs in Ottawa, Kitchener, Peel and Waterloo.

567 events of major epidemiological importance, such as the onset of epidemiologically relevant
568 variants, the rate of change appears to correlate with the disease burden. As an example, the
569 direction and rate of change in the WC ratio during the onset of the Alpha and Omicron variants
570 were similar and distinctly different from the period of onset of the Delta variant in Ottawa. An
571 apparent distinction between the onset of Alpha and Delta variants also exists in the studied
572 communities with the required data (% allelic proportions calculated for Alpha and Delta variants).

573 To determine the statistical significance of the change in WC ratio in Ottawa during the Omicron
574 VOC onset, a non-parametric Mann-Whitney U test was performed, and the corresponding p-
575 value was calculated. The WC ratio before the Omicron VOC onset had a mean of 1.7×10^{-6} (IQR
576 = $1.2 \times 10^{-6} - 1.8 \times 10^{-6}$), while the mean after the Omicron VOC onset was of 1.0×10^{-6} (IQR =
577 $7.2 \times 10^{-7} - 1.3 \times 10^{-6}$). As hypothesized, the onset of a more infectious VOC (Omicron)
578 corresponded with a decrease in WC ratio (p-value < 0.035).

579 It is important that in the interpretation of shifts in the WC ratio, relative changes are to be
580 investigated, rather than absolute changes, due to the site-specific nature of the WC ratio. Slight
581 modifications to methodologies and techniques in the laboratory, as well as molecular targets
582 analyzed, could cause differences in measurements, and therefore change the magnitude of the
583 WC significantly. This is observed in this study as the different laboratories employ similar
584 methods, but intricate differences regarding sample processing volumes and sample solids mass
585 appear to significantly affect results and the feasibility of direct comparisons. Furthermore, it is
586 important to also acknowledge that in this study, 5 of the 7 studied communities (Ottawa, Toronto,
587 Kitchener, Peel, and Waterloo) were in one province (Ontario), while the 2 other communities
588 (Edmonton and Calgary) were situated in another (Alberta), which may have led to slight
589 differences in both employed epidemic control measures and access to PCR testing, which could
590 also influence the WC ratio. There still exists a gap of knowledge in normalizing the WC ratio
591 before it could be used to compare data sets from completely different communities, however, on
592 a single community level, or in instances where a single, unified methodology and analysis is
593 applied, comparisons of the WC ratio between communities should also be possible.

594 **4 Conclusions**

595 This study strongly suggests that regular, daily monitoring of the WC ratio can reveal and
596 detect the onset of changes in disease transmission patterns, and the arrival/onset and waning
597 of more infectious variants or mutations of a pathogen or disease. When using traditional clinical
598 case data and WWS, additional monitoring of the WC ratio may provide a greater understanding
599 of the surveillance metrics during events of high epidemiological importance. The specific
600 conclusions of this study are as follows: During periods of resurgence or increases in disease
601 spread in a community, monitoring of reported clinical cases may provide a limited understanding
602 of the true disease prevalence rates when community daily clinical testing is restricted or
603 insufficient. The WC ratio will strongly increase when the disease burden increases in a
604 community where an insufficient number of clinical tests are being performed to adequately
605 approximate the disease burden in the community. Furthermore, if a community is not well
606 immunized (less than 2.5% of individuals have received two doses of a COVID-19 vaccine), based
607 on observed trends in this study, the onset of new, more infectious VOCs may lead to a decrease
608 in the WC ratio. Meanwhile, if a community is well immunized (>60.0% of residents have received
609 two doses of a COVID-19 vaccine), the onset of new, more infectious VOCs caused modest
610 decreases in the WC ratio. Moreover, the onset of the Omicron VOC resulted in significant
611 decreases in the WC ratio, as was observed during Alpha VOC dominance in early 2021, and
612 this, irrespective of the immunization status of the community, is likely due to the immune escape
613 capability of the Omicron VOC. It was observed that as a result, decreases in the WC can often
614 be associated with the onset of a change in disease dynamics and the arrival of more infectious
615 novel variants in the community and could be used as a tool to identify the emergence of new
616 variants in the future. Finally, it was determined that changes in the magnitude and inflection
617 points in the WC ratio at a longitudinally surveyed location may be indicative of changes in disease

618 burden and the ability of the pathogen to spread. These findings indicate that monitoring the WC
619 ratio during the SARS-CoV-2 pandemic and other, future pandemics, will yield additional insight
620 into the disease burden in a community and should be performed where possible.

621 **Declaration of competing interests**

622 The authors declare that no known competing financial interests or personal relationships
623 influenced the work reported in this manuscript.

624 **Acknowledgements**

625 The authors wish to acknowledge the help and assistance of the University of Ottawa, the
626 University of Toronto, the University of Waterloo, and the University of Alberta for their important
627 contributions to the laboratories performing wastewater analysis. Furthermore, authors are very
628 thankful of the support and continued cooperation of all wastewater treatment facility operators
629 (City of Ottawa, the City of Toronto, the City of Waterloo, the Region of Peel, the City of Kitchener,
630 EPCOR Utilities and the City of Calgary). Additional thanks go out to the Ottawa Hospital, the
631 Children's Hospital of Eastern Ontario, the Children's Hospital of Eastern Ontario's Research
632 Institute, Ottawa Public Health, Toronto Public Health, Peel Public Health, the Region of Waterloo
633 Public Health and Emergency Services, Public Health Ontario and all their employees involved in
634 the project during this study. Their time, facilities, resources, and thoughts provided throughout
635 the study helped the authors greatly.

636 **Funding**

637 This research was funded and supported by Ontario's Ministry of Environment,
638 Conservation and Parks SARS-CoV-2 surveillance initiative (awarded to the University of Ottawa,
639 the University of Toronto, and the University of Waterloo), by CHEO (Children's Hospital of
640 Eastern Ontario) CHAMO (Children's Hospital Academic Medical Organization) (awarded to Dr.
641 Alex E. MacKenzie) and by CIHR/Alberta Health/Alberta Innovates (awarded to Dr. Xiao-Li Pang).

642 **References**

- 643 Ahmed, W., Angel, N., Edson, J., Bibby, K., Bivins, A., O'Brien, J.W., Choi, P.M., Kitajima, M.,
644 Simpson, S.L., Li, J., Tschärke, B., Verhagen, R., Smith, W.J.M., Zaugg, J., Dierens, L.,
645 Hugenholtz, P., Thomas, K. V., Mueller, J.F., 2020. First confirmed detection of SARS-CoV-
646 2 in untreated wastewater in Australia: A proof of concept for the wastewater surveillance of
647 COVID-19 in the community. *Sci. Total Environ.* 728, 138764.
648 <https://doi.org/10.1016/j.scitotenv.2020.138764>
- 649 Ahmed, W., Simpson, S.L., Bertsch, P.M., Bibby, K., Bivins, A., Blackall, L.L., Bofill-Mas, S.,
650 Bosch, A., Brandão, J., Choi, P.M., Ciesielski, M., Donner, E., D'Souza, N., Farnleitner, A.H.,
651 Gerrity, D., Gonzalez, R., Griffith, J.F., Gyawali, P., Haas, C.N., Hamilton, K.A.,
652 Hapuarachchi, H.C., Harwood, V.J., Haque, R., Jackson, G., Khan, S.J., Khan, W., Kitajima,
653 M., Korajkic, A., La Rosa, G., Layton, B.A., Lipp, E., McLellan, S.L., McMinn, B., Medema,
654 G., Metcalfe, S., Meijer, W.G., Mueller, J.F., Murphy, H., Naughton, C.C., Noble, R.T.,
655 Payyappat, S., Petterson, S., Pitkänen, T., Rajal, V.B., Reyneke, B., Roman, F.A., Rose,
656 J.B., Rusiñol, M., Sadowsky, M.J., Sala-Comorera, L., Setoh, Y.X., Sherchan, S.P.,
657 Sirikanchana, K., Smith, W., Steele, J.A., Subburg, R., Symonds, E.M., Thai, P., Thomas, K.
658 V., Tynan, J., Toze, S., Thompson, J., Whiteley, A.S., Wong, J.C.C., Sano, D., Wuertz, S.,
659 Xagorarakis, I., Zhang, Q., Zimmer-Faust, A.G., Shanks, O.C., 2022. Minimizing errors in RT-
660 PCR detection and quantification of SARS-CoV-2 RNA for wastewater surveillance. *Sci.*
661 *Total Environ.* 805. <https://doi.org/10.1016/j.scitotenv.2021.149877>
- 662 Al Huraimel, K., Alhosani, M., Kunhabdulla, S., Stietiya, M.H., 2020. SARS-CoV-2 in the
663 environment: Modes of transmission, early detection and potential role of pollutions. *Sci.*
664 *Total Environ.* 744, 140946. <https://doi.org/10.1016/j.scitotenv.2020.140946>

- 665 Badu, K., Oyebola, K., Zahouli, J.Z.B., Fagbamigbe, A.F., de Souza, D.K., Dukhi, N., Amankwaa,
666 E.F., Tolba, M.F., Sylverken, A.A., Mosi, L., Mante, P.K., Matoke-Muhia, D., Goonoo, N.,
667 2021. SARS-CoV-2 Viral Shedding and Transmission Dynamics: Implications of WHO
668 COVID-19 Discharge Guidelines. *Front. Med.* 8, 1–11.
669 <https://doi.org/10.3389/fmed.2021.648660>
- 670 Bibby, K., Bivins, A., Wu, Z., North, D., 2021a. Making waves : Plausible lead time for wastewater
671 based epidemiology as an early warning system for COVID-19. *Water Res.* 202, 117438.
672 <https://doi.org/10.1016/j.watres.2021.117438>
- 673 Bibby, K., Bivins, A., Wu, Z., North, D., 2021b. Making waves: Plausible lead time for wastewater
674 based epidemiology as an early warning system for COVID-19. *Water Res.* 202, 117438.
675 <https://doi.org/10.1016/j.watres.2021.117438>
- 676 Bivins, A., Bibby, K., 2021. Wastewater Surveillance during Mass COVID-19 Vaccination on a
677 College Campus. *Environ. Sci. Technol. Lett.* 8, 792–798.
678 <https://doi.org/10.1021/acs.estlett.1c00519>
- 679 Bivins, A., North, D., Ahmad, A., Ahmed, W., Alm, E., Been, F., Bhattacharya, P., Bijlsma, L.,
680 Boehm, A.B., Brown, J., Buttiglieri, G., Calabro, V., Carducci, A., Castiglioni, S., Cetecioglu
681 Gurol, Z., Chakraborty, S., Costa, F., Curcio, S., De Los Reyes, F.L., Delgado Vela, J.,
682 Farkas, K., Fernandez-Casi, X., Gerba, C., Gerrity, D., Girones, R., Gonzalez, R., Haramoto,
683 E., Harris, A., Holden, P.A., Islam, M.T., Jones, D.L., Kasprzyk-Hordern, B., Kitajima, M.,
684 Kotlarz, N., Kumar, M., Kuroda, K., La Rosa, G., Malpei, F., Mautus, M., McLellan, S.L.,
685 Medema, G., Meschke, J.S., Mueller, J., Newton, R.J., Nilsson, D., Noble, R.T., Van Nuijs,
686 A., Peccia, J., Perkins, T.A., Pickering, A.J., Rose, J., Sanchez, G., Smith, A., Stadler, L.,
687 Stauber, C., Thomas, K., Van Der Voorn, T., Wigginton, K., Zhu, K., Bibby, K., 2020.

- 688 Wastewater-Based Epidemiology: Global Collaborative to Maximize Contributions in the
689 Fight against COVID-19. *Environ. Sci. Technol.* 54, 7754–7757.
690 <https://doi.org/10.1021/acs.est.0c02388>
- 691 Burki, T., 2021. Understanding variants of SARS-CoV-2. *Lancet* 397, 462.
692 [https://doi.org/10.1016/S0140-6736\(21\)00298-1](https://doi.org/10.1016/S0140-6736(21)00298-1)
- 693 Cao, Y., Francis, R., 2021. On forecasting the community-level COVID-19 cases from the
694 concentration of SARS-CoV-2 in wastewater. *Sci. Total Environ.* 786, 147451.
695 <https://doi.org/10.1016/j.scitotenv.2021.147451>
- 696 Cavany, S., Bivins, A., Wu, Z., North, D., Bibby, K., Perkins, T.A., 2022. Inferring SARS-CoV-2
697 RNA shedding into wastewater relative to the time of infection. *Epidemiol. Infect.* 150, 2–9.
698 <https://doi.org/10.1017/S0950268821002752>
- 699 Chakraborty, P., Pasupuleti, M., Jai Shankar, M.R., Bharat, G.K., Krishnasamy, S., Dasgupta,
700 S.C., Sarkar, S.K., Jones, K.C., 2021. First surveillance of SARS-CoV-2 and organic tracers
701 in community wastewater during post lockdown in Chennai, South India: Methods,
702 occurrence and concurrence. *Sci. Total Environ.* 778, 146252.
703 <https://doi.org/10.1016/j.scitotenv.2021.146252>
- 704 Challen, R., Brooks-Pollock, E., Read, J.M., Dyson, L., Tsaneva-Atanasova, K., Danon, L., 2021.
705 Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched
706 cohort study. *BMJ* 372, 1–10. <https://doi.org/10.1136/bmj.n579>
- 707 Chen, Y., Chen, L., Deng, Q., Zhang, G., Wu, K., Ni, L., Yang, Y., Liu, B., Wang, W., Wei, C.,
708 Yang, J., Ye, G., Cheng, Z., 2020. The presence of SARS-CoV-2 RNA in the feces of COVID-
709 19 patients. *J. Med. Virol.* 92, 833–840. <https://doi.org/10.1002/jmv.25825>

- 710 Cherian, S., Potdar, V., Jadhav, Santosh, Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S.,
711 Abraham, P., Panda, S., Patil, S., Jagtap, P., Kasabe, B., Shah, U., Sanjeev, T., Divekar, G.,
712 Korabu, K., Shelkande, S., Shinde, P., Zakiuddin, S., Vipat, V., Jadhav, Sheetal, Iyengar, K.,
713 Malik, V., Bhorekar, S., Kumar, A., Sahay, R., 2021. Convergent evolution of SARS-CoV-2
714 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in
715 Maharashtra, India. bioRxiv 2021.04.22.440932.
- 716 Chik, A.H.S., Glier, M.B., Servos, M., Mangat, C.S., Pang, X.L., Qiu, Y., D'Aoust, P.M., Burnet,
717 J.B., Delatolla, R., Dorner, S., Geng, Q., Giesy, J.P., McKay, R.M., Mulvey, M.R., Prystajecy,
718 N., Srikanthan, N., Xie, Y., Conant, B., Hruday, S.E., 2021. Comparison of approaches to
719 quantify SARS-CoV-2 in wastewater using RT-qPCR: Results and implications from a
720 collaborative inter-laboratory study in Canada. *J. Environ. Sci.* 107, 218–229.
721 <https://doi.org/10.1016/j.jes.2021.01.029>
- 722 China Center for Disease Control, 2020. The Epidemiological Characteristics of an Outbreak of
723 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020. *中华流行病学杂志* 41, 145–
724 151.
- 725 Crawley, M., Powers, L., Nasser, S., Jabakhanji, S., The Canadian Press, 2020. Ontario
726 implementing stricter public health measures as province sets COVID-19 case record | CBC
727 News [WWW Document]. CBC News Toronto. URL
728 [https://www.cbc.ca/news/canada/toronto/covid-19-coronavirus-ontario-october-2-](https://www.cbc.ca/news/canada/toronto/covid-19-coronavirus-ontario-october-2-1.5747709)
729 [1.5747709](https://www.cbc.ca/news/canada/toronto/covid-19-coronavirus-ontario-october-2-1.5747709) (accessed 9.10.21).
- 730 D'Aoust, P.M., Graber, T.E., Mercier, E., Montpetit, D., Alexandrov, I., Neault, N., Baig, A.T.,
731 Mayne, J., Zhang, X., Alain, T., Servos, M.R., Srikanthan, N., MacKenzie, M., Figeys, D.,
732 Manuel, D., Jüni, P., MacKenzie, A.E., Delatolla, R., 2021a. Catching a resurgence: Increase

733 in SARS-CoV-2 viral RNA identified in wastewater 48 h before COVID-19 clinical tests and
734 96 h before hospitalizations. *Sci. Total Environ.* 770.
735 <https://doi.org/10.1016/j.scitotenv.2021.145319>

736 D'Aoust, P.M., Towhid, S.T., Mercier, É., Hegazy, N., Tian, X., Bhatnagar, K., Zhang, Z.,
737 Naughton, C.C., MacKenzie, A.E., Graber, T.E., Delatolla, R., 2021b. COVID-19 wastewater
738 surveillance in rural communities: Comparison of lagoon and pumping station samples. *Sci.*
739 *Total Environ.* 801, 149618. <https://doi.org/10.1016/j.scitotenv.2021.149618>

740 da Rocha Araujo, F.A.G., 2020. Uses and limits of the clinical laboratory in the COVID-19
741 pandemic: A didactic review. *Rev. Assoc. Med. Bras.* 66, 1718–1724.
742 <https://doi.org/10.1590/1806-9282.66.12.1718>

743 Drake, J.W., Holland, J.J., 1999. Mutation rates among RNA viruses 1999, 18–21.

744 Duffy, S., 2018. Why are RNA virus mutation rates so damn high? *PLoS Biol.* 16, 1–6.
745 <https://doi.org/10.1371/journal.pbio.3000003>

746 Fajnzylber, J., Regan, J., Coxen, K., Corry, H., Wong, C., Rosenthal, A., Worrall, D., Giguél, F.,
747 Piechocka-Trocha, A., Atyeo, C., Fischinger, S., Chan, A., Flaherty, K.T., Hall, K., Dougan,
748 M., Ryan, E.T., Gillespie, E., Chishti, R., Li, Y., Jilg, N., Hanidziar, D., Baron, R.M., Baden,
749 L., Tsibris, A.M., Armstrong, K.A., Kuritzkes, D.R., Alter, G., Walker, B.D., Yu, X., Li, J.Z.,
750 Abayneh, B.A. (Betty), Allen, P., Antille, D., Balazs, A., Bals, J., Barbash, M., Bartsch, Y.,
751 Boucau, J., Boyce, S., Braley, J., Branch, K., Broderick, K., Carney, J., Chevalier, J.,
752 Choudhary, M.C., Chowdhury, N., Cordwell, T., Daley, G., Davidson, S., Desjardins, M.,
753 Donahue, L., Drew, D., Einkauf, K., Elizabeth, S., Elliman, A., Etemad, B., Fallon, J., Fedirko,
754 L., Finn, K., Flannery, J., Forde, P., Garcia-Broncano, P., Gettings, E., Golan, D., Goodman,
755 K., Griffin, A., Grimmel, S., Grinke, K., Hartana, C.A., Healy, M., Heller, H., Henault, D.,
46

756 Holland, G., Jiang, C., Jordan, H., Kaplonek, P., Karlson, E.W., Karpell, M., Kayitesi, C., Lam,
757 E.C., LaValle, V., Lefteri, K., Lian, X., Lichterfeld, M., Lingwood, D., Liu, H., Liu, J., Lopez,
758 K., Lu, Y., Luthern, S., Ly, N.L., MacGowan, M., Magispoc, K., Marchewka, J., Martino, B.,
759 McNamara, R., Michell, A., Millstrom, I., Miranda, N., Nambu, C., Nelson, S., Noone, M.,
760 Novack, L., O'Callaghan, C., Ommerborn, C., Osborn, M., Pacheco, L.C., Phan, N., Pillai,
761 S., Porto, F.A., Rassadkina, Y., Reissis, A., Ruzicka, F., Seiger, K., Selleck, K., Sessa, L.,
762 Sharpe, A., Sharr, C., Shin, S., Singh, N., Slaughenhaupt, S., Sheppard, K.S., Sun, W., Sun,
763 X., Suschana, E. (Lizzie), Talabi, O., Ticheli, H., Weiss, S.T., Wilson, V., Zhu, A., 2020.
764 SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nat.*
765 *Commun.* 11, 1–9. <https://doi.org/10.1038/s41467-020-19057-5>

766 Fontana, L., Villamagna, A.H., Sikka, M.K., McGregor, J.C., 2020. Understanding Viral Shedding
767 of SARS-CoV-2: Review of Current Literature. *Infect. Control Hosp. Epidemiol.* 2, 1–10.
768 <https://doi.org/10.1017/ice.2020.1273>

769 Frampton, D., Rampling, T., Cross, A., Bailey, H., Heaney, J., Byott, M., Scott, R., Sconza, R.,
770 Price, J., Margaritis, M., Bergstrom, M., Spyer, M.J., Miralhes, P.B., Grant, P., Kirk, S.,
771 Valerio, C., Mangera, Z., Prabhakar, T., Moreno-Cuesta, J., Arulkumaran, N., Singer, M.,
772 Shin, G.Y., Sanchez, E., Paraskevopoulou, S.M., Pillay, D., McKendry, R.A., Mirfenderesky,
773 M., Houlihan, C.F., Nastouli, E., 2021. Genomic characteristics and clinical effect of the
774 emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and
775 hospital-based cohort study. *Lancet Infect. Dis.* 21, 1246–1256.
776 [https://doi.org/10.1016/S1473-3099\(21\)00170-5](https://doi.org/10.1016/S1473-3099(21)00170-5)

777 Galani, A., Aalizadeh, R., Kostakis, M., Markou, A., Alygizakis, N., Lytras, T., Adamopoulos, P.G.,
778 Peccia, J., Thompson, D.C., Kontou, A., Karagiannidis, A., Lianidou, E.S., Avgeris, M.,
779 Paraskevis, D., Tsiodras, S., Scorilas, A., Vasiliou, V., Dimopoulos, M.A., Thomaidis, N.S.,

780 2022. SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU
781 admissions. Sci. Total Environ. 804, 150151.
782 <https://doi.org/10.1016/j.scitotenv.2021.150151>

783 Galloway, S.E., Paul, P., MacCannell, D.R., Johansson, M.A., Brooks, J.T., MacNeil, A., Slayton,
784 R.B., Tong, S., Silk, B.J., Armstrong, G.L., Biggerstaff, M., Dugan, V.G., 2021. Emergence
785 of SARS-CoV-2 B.1.1.7 Lineage. *Morb. Mortal. Wkly. Rep.* 70, 95–99.

786 Gonsalves, G., Yamey, G., 2020. Political interference in public health science during covid-19.
787 *BMJ* 371, 19–20. <https://doi.org/10.1136/bmj.m3878>

788 Government of Alberta, 2021. COVID-19 Alberta statistics | alberta.ca [WWW Document]. URL
789 <https://www.alberta.ca/stats/covid-19-alberta-statistics.htm> (accessed 1.11.22).

790 Government of Canada, 2021. COVID-19 vaccination coverage in Canada - Canada.ca [WWW
791 Document]. URL <https://health-infobase.canada.ca/covid-19/vaccination-coverage/>
792 (accessed 3.8.22).

793 Graber, T.E., Mercier, É., Bhatnagar, K., Fuzzen, M., D'Aoust, P.M., Hoang, H.-D., Tian, X.,
794 Towhid, S.T., Diaz, J.P., Eid, W., Alain, T., Butler, A., Goodridge, L., Servos, M., Delatolla,
795 R., 2021. Near real-time determination of B.1.1.7 in proportion to total SARS-CoV-2 viral
796 load in wastewater using an allele-specific primer extension PCR strategy. *Water Res.* 205,
797 117681. <https://doi.org/10.1016/j.watres.2021.117681>

798 Graham, M.S., Sudre, C.H., May, A., Antonelli, M., Murray, B., Varsavsky, T., Kläser, K., Canas,
799 L.S., Molteni, E., Modat, M., Drew, D.A., Nguyen, L.H., Polidori, L., Selvachandran, S., Hu,
800 C., Capdevila, J., Koshy, C., Ash, A., Wise, E., Moore, N., Mori, M., Cortes, N., Lynch, J.,
801 Kidd, S., Fairley, D.J., Curran, T., McKenna, J.P., Adams, H., Fraser, C., Golubchik, T.,

802 Bonsall, D., Hassan-Ibrahim, M.O., Malone, C.S., Cogger, B.J., Wantoch, M., Reynolds, N.,
803 Warne, B., Maksimovic, J., Spellman, K., McCluggage, K., John, M., Beer, R., Afifi, S.,
804 Morgan, S., Marchbank, A., Price, A., Kitchen, C., Gulliver, H., Merrick, I., Southgate, J.,
805 Guest, M., Munn, R., Workman, T., Connor, T.R., Fuller, W., Bresner, C., Snell, L.B., Patel,
806 A., Charalampous, T., Nebbia, G., Batra, R., Edgeworth, J., Robson, S.C., Beckett, A.H.,
807 Aanensen, D.M., Underwood, A.P., Yeats, C.A., Abudahab, K., Taylor, B.E., Menegazzo, M.,
808 Clark, G., Smith, W., Khakh, M., Fleming, V.M., Lister, M.M., Howson-Wells, H.C., Berry,
809 Louise, Boswell, T., Joseph, A., Willingham, I., Jones, C., Holmes, C., Bird, P., Helmer, T.,
810 Fallon, K., Tang, J., Raviprakash, V., Campbell, S., Sheriff, N., Blakey, V., Williams, L.A.,
811 Loose, M.W., Holmes, N., Moore, Christopher, Carlile, M., Wright, V., Sang, F., Debebe, J.,
812 Coll, F., Signell, A.W., Betancor, G., Wilson, H.D., Eldirdiri, S., Kenyon, A., Davis, T., Pybus,
813 O.G., du Plessis, L., Zarebski, A.E., Raghwani, J., Kraemer, M.U., Francois, S., Attwood,
814 S.W., Vasylyeva, T.I., Escalera Zamudio, M., Gutierrez, B., Torok, M.E., Hamilton, W.L.,
815 Goodfellow, I.G., Hall, G., Jahun, A.S., Chaudhry, Y., Hosmillo, M., Pinckert, M.L., Georgana,
816 I., Moses, S., Lowe, H., Bedford, L., Moore, J., Stonehouse, S., Fisher, C.L., Awan, A.R.,
817 BoYes, J., Breuer, J., Harris, K.A., Brown, J.R., Shah, D., Atkinson, L., Lee, J.C., Storey, N.,
818 Flaviani, F., Alcolea-Medina, A., Williams, R., Vernet, G., Chapman, M.R., Levett, L.J.,
819 Heaney, J., Chatterton, W., Pusok, M., Xu-McCrae, L., Smith, D.L., Bashton, M., Young,
820 G.R., Holmes, A., Randell, P.A., Cox, A., Madona, P., Bolt, F., Price, J., Mookerjee, S.,
821 Ragonnet-Cronin, M., Nascimento, F.F., Jorgensen, D., Siveroni, I., Johnson, R., Boyd, O.,
822 Geidelberg, L., Volz, E.M., Rowan, A., Taylor, G.P., Smollett, K.L., Loman, N.J., Quick, J.,
823 McMurray, C., Stockton, J., Nicholls, S., Rowe, W., Poplawski, R., McNally, A., Martinez
824 Nunez, R.T., Mason, J., Robinson, T.I., O'Toole, E., Watts, J., Breen, C., Cowell, A., Sluga,
825 G., Machin, N.W., Ahmad, S.S.Y., George, R.P., Halstead, F., Sivaprakasam, V., Hogsden,
826 W., Illingworth, C.J., Jackson, C., Thomson, E.C., Shepherd, J.G., Asamaphan, P., Niebel,

827 M.O., Li, K.K., Shah, R.N., Jesudason, N.G., Tong, L., Broos, A., Mair, D., Nichols, J.,
828 Carmichael, S.N., Nomikou, K., Aranday-Cortes, E., Johnson, N., Starinskij, I., da Silva Filipe,
829 A., Robertson, D.L., Orton, R.J., Hughes, J., Vattipally, S., Singer, J.B., Nickbakhsh, S., Hale,
830 A.D., Macfarlane-Smith, L.R., Harper, K.L., Carden, H., Taha, Y., Payne, B.A., Burton-
831 Fanning, S., Waugh, S., Collins, J., Eltringham, G., Rushton, S., O'Brien, S., Bradley, A.,
832 Maclean, A., Mollett, G., Blacow, R., Templeton, K.E., McHugh, M.P., Dewar, R., Wastenge,
833 E., Dervisevic, S., Stanley, R., Meader, E.J., Coupland, L., Smith, L., Graham, C., Barton,
834 E., Padgett, D., Scott, G., Swindells, E., Greenaway, J., Nelson, A., McCann, C.M., Yew,
835 W.C., Andersson, M., Peto, T., Justice, A., Eyre, D., Crook, D., Sloan, T.J., Duckworth, N.,
836 Walsh, S., Chauhan, A.J., Glaysher, S., Bicknell, K., Wyllie, S., Elliott, S., Lloyd, A., Impey,
837 R., Levene, N., Monaghan, L., Bradley, D.T., Wyatt, T., Allara, E., Pearson, C., Osman, H.,
838 Bosworth, A., Robinson, E., Muir, P., Vipond, I.B., Hopes, R., Pymont, H.M., Hutchings, S.,
839 Curran, M.D., Parmar, S., Lackenby, A., Mbisa, T., Platt, S., Miah, S., Bibby, D., Manso, C.,
840 Hubb, J., Chand, M., Dabrera, G., Ramsay, M., Bradshaw, D., Thornton, A., Myers, R.,
841 Schaefer, U., Groves, N., Gallagher, E., Lee, D., Williams, D., Ellaby, N., Harrison, I.,
842 Hartman, H., Manesis, N., Patel, V., Bishop, C., Chalker, V., Ledesma, J., Twohig, K.A.,
843 Holden, M.T.G., Shaaban, S., Birchley, A., Adams, A., Davies, A., Gaskin, A., Plimmer, A.,
844 Gatica-Wilcox, B., McKerr, C., Moore, Catherine, Williams, C., Heyburn, D., De Lacy, E.,
845 Hilvers, E., Downing, F., Shankar, G., Jones, H., Asad, H., Coombes, J., Watkins, J., Evans,
846 J.M., Fina, L., Gifford, L., Gilbert, L., Graham, L., Perry, M., Morgan, M., Bull, M., Cronin, M.,
847 Pacchiarini, N., Craine, N., Jones, R., Howe, R., Corden, S., Rey, S., Kumziene-
848 SummerhaYes, S., Taylor, S., Cottrell, S., Jones, S., Edwards, S., O'Grady, J., Page, A.J.,
849 Mather, A.E., Baker, D.J., Rudder, S., Aydin, A., Kay, G.L., Trotter, A.J., Alikhan, N.F., de
850 Oliveira Martins, L., Le-Viet, T., Meadows, L., Casey, A., Ratcliffe, L., Simpson, D.A., Molnar,
851 Z., Thompson, T., Acheson, E., Masoli, J.A., Knight, B.A., Ellard, S., Auckland, C., Jones,

852 C.R., Mahungu, T.W., Irish-Tavares, D., Haque, T., Hart, J., Witele, E., Fenton, M.L., Dadrah,
853 A., Symmonds, A., Saluja, T., Bourgeois, Y., Scarlett, G.P., Loveson, K.F., Goudarzi, S.,
854 Fearn, C., Cook, K., Dent, H., Paul, H., Partridge, D.G., Raza, M., Evans, C., Johnson, K.,
855 Liggett, S., Baker, P., Bonner, S., Essex, S., Lyons, R.A., Saeed, K., Mahanama, A.I.K.,
856 Samaraweera, B., Silveira, S., Pelosi, E., Wilson-Davies, E., Williams, R.J., Kristiansen, M.,
857 Roy, S., Williams, C.A., Cotic, M., Bayzid, N., Westhorpe, A.P., Hartley, J.A., Jannoo, R.,
858 Lowe, H.L., Karamani, A., Ensell, L., Prieto, J.A., Jeremiah, S., Grammatopoulos, D., Pandey,
859 S., Berry, Lisa, Jones, K., Richter, A., Beggs, A., Best, A., Percival, B., Mirza, J., Megram,
860 O., Mayhew, M., Crawford, L., Ashcroft, F., Moles-Garcia, E., Cumley, N., Smith, C.P., Bucca,
861 G., Hesketh, A.R., Blane, B., Girgis, S.T., Leek, D., Sridhar, S., Forrest, S., Cormie, C., Gill,
862 H.K., Dias, J., Higginson, E.E., Maes, M., Young, J., Kermack, L.M., Gupta, R.K., Ludden,
863 C., Peacock, S.J., Palmer, Sophie, Churcher, C.M., Hadjirin, N.F., Carabelli, A.M., Brooks,
864 E., Smith, K.S., Galai, K., McManus, G.M., Ruis, C., Davidson, R.K., Rambaut, A., Williams,
865 T., Balcazar, C.E., Gallagher, M.D., O'Toole, Á., Rooke, S., Hill, V., Williamson, K.A., Stanton,
866 T.D., Michell, S.L., Bewshea, C.M., Temperton, B., Michelsen, M.L., Warwick-Dugdale, J.,
867 Manley, R., Farbos, A., Harrison, J.W., Sambles, C.M., Studholme, D.J., Jeffries, A.R., Darby,
868 A.C., Hiscox, J.A., Paterson, S., Iturriza-Gomara, M., Jackson, K.A., Lucaci, A.O., Vamos,
869 E.E., Hughes, M., Rainbow, L., Eccles, R., Nelson, C., Whitehead, M., Turtle, L., Haldenby,
870 S.T., Gregory, R., Gemmell, M., Wierzbicki, C., Webster, H.J., de Silva, T.I., Smith, N.,
871 Angyal, A., Lindsey, B.B., Groves, D.C., Green, L.R., Wang, D., Freeman, T.M., Parker, M.D.,
872 Keeley, A.J., Parsons, P.J., Tucker, R.M., Brown, R., Wyles, M., Whiteley, M., Zhang, P.,
873 Gallis, M., Louka, S.F., Constantinidou, C., Unnikrishnan, M., Ott, S., Cheng, J.K.J.,
874 Bridgewater, H.E., Frost, L.R., Taylor-Joyce, G., Stark, R., Baxter, L., Alam, M.T., Brown,
875 P.E., Aggarwal, D., Cerda, A.C., Merrill, T. V., Wilson, R.E., McClure, P.C., Chappell, J.G.,
876 Tsoleridis, T., Ball, J., Buck, D., Todd, J.A., Green, A., Trebes, A., MacIntyre-Cockett, G., de

877 Cesare, M., Alderton, A., Amato, R., Ariani, C. V., Beale, M.A., Beaver, C., Bellis, K.L.,
878 Betteridge, E., Bonfield, J., Danesh, J., Dorman, M.J., Drury, E., Farr, B.W., Foulser, L.,
879 Goncalves, S., Goodwin, S., Gourtovaia, M., Harrison, E.M., Jackson, D.K., Jamrozy, D.,
880 Johnston, I., Kane, L., Kay, S., Keatley, J.P., Kwiatkowski, D., Langford, C.F., Lawniczak,
881 M., Letchford, L., Livett, R., Lo, S., Martincorena, I., McGuigan, S., Nelson, R., Palmer, Steve,
882 Park, N.R., Patel, M., Prestwood, L., Puethe, C., Quail, M.A., Rajatileka, S., Scott, C., Shirley,
883 L., Sillitoe, J., Spencer Chapman, M.H., Thurston, S.A., Tonkin-Hill, G., Weldon, D., Rajan,
884 D., Bronner, I.F., Aigrain, L., Redshaw, N.M., Lensing, S. V., Davies, R., Whitwham, A.,
885 Liddle, J., Lewis, K., Tovar-Corona, J.M., Leonard, S., Durham, J., Bassett, A.R., McCarthy,
886 S., Moll, R.J., James, K., Oliver, K., Makunin, A., Barrett, J., Gunson, R.N., Hammers, A.,
887 Chan, A.T., Wolf, J., Spector, T.D., Steves, C.J., Ourselin, S., 2021. Changes in
888 symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant
889 B.1.1.7: an ecological study. *Lancet Public Heal.* 6, e335–e345.
890 <https://doi.org/10.1101/2021.03.28.21254404>

891 Halfmann, P.J., Iida, S., Iwatsuki-Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S.M., Darling,
892 T.L., Joshi, A., Loeber, S., Singh, G., Foster, S.L., Ying, B., Case, J.B., Chong, Z., Whitener,
893 B., Moliva, J., Floyd, K., Ujie, M., Nakajima, N., Ito, M., Wright, R., Uraki, R., Warang, P.,
894 Gagne, M., Li, R., Sakai-Tagawa, Y., Liu, Y., Larson, D., Osorio, J.E., Hernandez-Ortiz, J.P.,
895 Henry, A.R., Ciouderis, K., Florek, K.R., Patel, M., Odle, A., Wong, L.-Y.R., Bateman, A.C.,
896 Wang, Z., Edara, V.-V., Chong, Z., Franks, J., Jeevan, T., Fabrizio, T., DeBeauchamp, J.,
897 Kercher, L., Seiler, P., Gonzalez-Reiche, A.S., Sordillo, E.M., Chang, L.A., van Bakel, H.,
898 Simon, V., Albuquerque, B., Alshammary, H., Amoako, A.A., Aslam, S., Banu, R., Cognigni,
899 C., Espinoza-Moraga, M., Farrugia, K., van de Guchte, A., Khalil, Z., Laporte, M., Mena, I.,
900 Paniz-Mondolfi, A.E., Polanco, J., Rooker, A., Sominsky, L.A., Douek, D.C., Sullivan, N.J.,
901 Thackray, L.B., Ueki, H., Yamayoshi, S., Imai, M., Perlman, S., Webby, R.J., Seder, R.A.,

- 902 Suthar, M.S., García-Sastre, A., Schotsaert, M., Suzuki, T., Boon, A.C.M., Diamond, M.S.,
903 Kawaoka, Y., 2022. SARS-CoV-2 Omicron virus causes attenuated disease in mice and
904 hamsters. *Nature* 1–22. <https://doi.org/10.1038/s41586-022-04441-6>
- 905 Hatchette, T.F., 2009. The limitations of point of care testing for pandemic influenza: What
906 Clinicians and Public Health professionals need to know. *Can. J. Public Heal.* 100, 204–207.
907 <https://doi.org/10.1007/bf03405541>
- 908 He, X., Hong, W., Pan, X., Lu, G., Wei, X., 2021. SARS-CoV-2 Omicron variant: Characteristics
909 and prevention. *MedComm* 2, 838–845. <https://doi.org/10.1002/mco2.110>
- 910 Hirotsu, Y., Maejima, M., Shibusawa, M., Nagakubo, Y., Hosaka, K., Amemiya, K., Sueki, H.,
911 Hayakawa, M., Mochizuki, H., Tsutsui, T., Kakizaki, Y., Miyashita, Y., Yagi, S., Kojima, S.,
912 Omata, M., 2020. Comparison of automated SARS-CoV-2 antigen test for COVID-19
913 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven
914 serially followed patients. *Int. J. Infect. Dis.* 99, 397–402.
915 <https://doi.org/10.1016/j.ijid.2020.08.029>
- 916 Holmes, E.G., Rambaut, A., 2004. Viral evolution and the emergence of SARS coronavirus. *Philos.*
917 *Trans. R. Soc. B Biol. Sci.* 359, 1059–1065. <https://doi.org/10.1098/rstb.2004.1478>
- 918 Hoseinpour Dehkordi, A., Alizadeh, M., Derakhshan, P., Babazadeh, P., Jahandideh, A., 2020.
919 Understanding epidemic data and statistics: A case study of COVID-19. *J. Med. Virol.* 92,
920 868–882. <https://doi.org/10.1002/jmv.25885>
- 921 Hua, C.Z., Miao, Z.P., Zheng, J.S., Huang, Q., Sun, Q.F., Lu, H.P., Su, F.F., Wang, W.H., Huang,
922 L.P., Chen, D.Q., Xu, Z.W., Ji, L.D., Zhang, H.P., Yang, X.W., Li, M.H., Mao, Y.Y., Ying, M.Z.,
923 Ye, S., Shu, Q., Chen, E.F., Liang, J.F., Wang, W., Chen, Z.M., Li, W., Fu, J.F., 2020.

- 924 Epidemiological features and viral shedding in children with SARS-CoV-2 infection. *J. Med.*
925 *Virol.* 92, 2804–2812. <https://doi.org/10.1002/jmv.26180>
- 926 Huang, Y., Chen, S., Yang, Z., Guan, W., Liu, D., Lin, Z., Zhang, Y., Xu, Z., Liu, X., Li, Y., 2020.
927 SARS-CoV-2 viral load in clinical samples from critically ill patients. *Am. J. Respir. Crit. Care*
928 *Med.* 201, 1435–1438. <https://doi.org/10.1164/rccm.202003-0572LE>
- 929 Hyafil, A., Moriña, D., 2020. Analysis of the impact of lockdown on the reproduction number of
930 the SARS-Cov-2 in Spain. *Gac. Sanit.* <https://doi.org/10.1016/j.gaceta.2020.05.003>
- 931 Jaiswal, J., LoSchiavo, C., Perlman, D.C., 2020. Disinformation, Misinformation and Inequality-
932 Driven Mistrust in the Time of COVID-19: Lessons Unlearned from AIDS Denialism. *AIDS*
933 *Behav.* 24, 2776–2780. <https://doi.org/10.1007/s10461-020-02925-y>
- 934 Jones, D.L., Baluja, M.Q., Graham, D.W., Corbishley, A., McDonald, J.E., Malham, S.K., Hillary,
935 L.S., Connor, T.R., Gaze, W.H., Moura, I.B., Wilcox, M.H., Farkas, K., 2020. Shedding of
936 SARS-CoV-2 in feces and urine and its potential role in person-to-person transmission and
937 the environment-based spread of COVID-19. *Sci. Total Environ.* 749, 141364.
938 <https://doi.org/10.1016/j.scitotenv.2020.141364>
- 939 Kannan, S.R., Spratt, A.N., Cohen, A.R., Naqvi, S.H., Chand, H.S., Quinn, T.P., Lorson, C.L.,
940 Byrareddy, S.N., Singh, K., 2021. Evolutionary analysis of the Delta and Delta Plus variants
941 of the SARS-CoV-2 viruses. *J. Autoimmun.* 124, 102715.
942 <https://doi.org/10.1016/j.jaut.2021.102715>
- 943 Karthikeyan, S., Ronquillo, N., Belda-ferre, P., Alvarado, D., Javidi, T., Longhurst, C.A., Knight,
944 R., 2021. High-Throughput Wastewater SARS-CoV-2 Detection Enables. *mSystems* 6, 1–6.
- 945 Khailaie, S., Mitra, T., Bandyopadhyay, A., Schips, M., Mascheroni, P., Vanella, P., Lange, B.,

- 946 Binder, S.C., Meyer-Hermann, M., 2021. Development of the reproduction number from
947 coronavirus SARS-CoV-2 case data in Germany and implications for political measures.
948 BMC Med. 19, 1–16. <https://doi.org/10.1186/s12916-020-01884-4>
- 949 Kolifarhood, G., Aghaali, M., Saadati, H.M., Taherpour, N., Rahimi, S., Izadi, N., Nazari, S.S.H.,
950 2020. Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. Arch. Acad.
951 Emerg. Med. 8, 1–9. <https://doi.org/10.22037/aaem.v8i1.620>
- 952 La Rosa, G., Bonadonna, L., Lucentini, L., Kenmoe, S., Suffredini, E., 2020. Coronavirus in water
953 environments: Occurrence, persistence and concentration methods - A scoping review.
954 Water Res. 179, 115899. <https://doi.org/10.1016/j.watres.2020.115899>
- 955 Lee, W.L., Imakaev, M., Armas, F., McElroy, K.A., Gu, X., Duvallet, C., Chandra, F., Chen, H.,
956 Leifels, M., Mendola, S., Floyd-O’Sullivan, R., Powell, M.M., Wilson, S.T., Berge, K.L.J., Lim,
957 C.Y.J., Wu, F., Xiao, A., Moniz, K., Ghaeli, N., Matus, M., Thompson, J., Alm, E.J., 2021.
958 Quantitative SARS-CoV-2 Alpha Variant B.1.1.7 Tracking in Wastewater by Allele-Specific
959 RT-qPCR. Environ. Sci. Technol. Lett. 8, 675–682.
960 <https://doi.org/10.1021/acs.estlett.1c00375>
- 961 Li, X., Zhang, S., Shi, J., Luby, S.P., Jiang, G., 2021. Uncertainties in estimating SARS-CoV-2
962 prevalence by wastewater-based epidemiology. Chem. Eng. J. 415, 129039.
963 <https://doi.org/10.1016/j.cej.2021.129039>
- 964 Ling, Y., Xu, S.B., Lin, Y.X., Tian, D., Zhu, Z.Q., Dai, F.H., Wu, F., Song, Z.G., Huang, W., Chen,
965 J., Hu, B.J., Wang, S., Mao, E.Q., Zhu, L., Zhang, W.H., Lu, H.Z., 2020. Persistence and
966 clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin. Med.
967 J. (Engl). 133, 1039–1043. <https://doi.org/10.1097/CM9.0000000000000774>

- 968 Liu, Y., Liu, J., Johnson, B.A., Xia, H., Ku, Z., Schindewolf, C., Widen, S.G., An, Z., Weaver, S.,
969 Menachery, V.D., Xie, X., Shi, P.-Y., 2021. Delta spike P681R mutation enhances SARS-
970 CoV-2 fitness over Alpha variant. *bioRxiv* 1, 2021.08.12.456173.
- 971 Long, Q.X., Tang, X.J., Shi, Q.L., Li, Q., Deng, H.J., Yuan, J., Hu, J.L., Xu, W., Zhang, Y., Lv, F.J.,
972 Su, K., Zhang, F., Gong, J., Wu, B., Liu, X.M., Li, J.J., Qiu, J.F., Chen, J., Huang, A.L., 2020.
973 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat. Med.*
974 <https://doi.org/10.1038/s41591-020-0965-6>
- 975 Malinverni, C., Brigagão, J.I.M., 2020. COVID-19: Scientific Arguments, Denialism, Eugenics, and
976 the Construction of the Antisocial Distancing Discourse in Brazil. *Front. Commun.* 5.
977 <https://doi.org/10.3389/fcomm.2020.582963>
- 978 McDermott, J.H., Newman, W.G., 2020. Refusal of viral testing during the SARS-CoV-2 pandemic.
979 *Clin. Med. J. R. Coll. Physicians London* 20, E163–E164.
980 <https://doi.org/10.7861/CLINMED.2020-0388>
- 981 Medema, G., Heijnen, L., Elsinga, G., Italiaander, R., Brouwer, A., 2020. Presence of SARS-
982 Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the
983 Early Stage of the Epidemic in The Netherlands. *Environ. Sci. Technol. Lett.* 7, 511–516.
984 <https://doi.org/10.1021/acs.estlett.0c00357>
- 985 Miura, F., Kitajima, M., Omori, R., 2021. Duration of SARS-CoV-2 viral shedding in faeces as a
986 parameter for wastewater-based epidemiology: Re-analysis of patient data using a shedding
987 dynamics model. *Sci. Total Environ.* 769, 144549.
988 <https://doi.org/10.1016/j.scitotenv.2020.144549>
- 989 Novoa, K.C., Dunn, T., Curry, A., Froude, R., Simpson, S.A., 2021. Limitations of Traditional

- 990 Models for Medical Decision-Making Capacity and Ethical Clinical Practice in Light of the
991 SARS-CoV-2 Pandemic. *Cureus* 13, 2–5. <https://doi.org/10.7759/cureus.14716>
- 992 O’Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D.A.T., Azman, A.S., Paireau, J.,
993 Fontanet, A., Cauchemez, S., Salje, H., 2021. Age-specific mortality and immunity patterns
994 of SARS-CoV-2. *Nature* 590, 140–145. <https://doi.org/10.1038/s41586-020-2918-0>
- 995 Olesen, S.W., Imakaev, M., Duvallet, C., 2021. Making waves: Defining the lead time of
996 wastewater-based epidemiology for COVID-19. *Water Res.* 202, 117433.
997 <https://doi.org/10.1016/j.watres.2021.117433>
- 998 Oran, D.P., Topol, E.J., 2020. Prevalence of asymptomatic SARS-CoV-2 infection. A narrative
999 review. *Ann. Intern. Med.* 173, 362–368. <https://doi.org/10.7326/M20-3012>
- 1000 Ottawa Public Health, 2021. Daily COVID-19 Dashboard - Ottawa Public Health [WWW
1001 Document]. URL [https://www.ottawapublichealth.ca/en/reports-research-and-](https://www.ottawapublichealth.ca/en/reports-research-and-statistics/daily-covid19-dashboard.aspx)
1002 [statistics/daily-covid19-dashboard.aspx](https://www.ottawapublichealth.ca/en/reports-research-and-statistics/daily-covid19-dashboard.aspx) (accessed 9.29.21).
- 1003 Pan, A., Liu, L., Wang, C., Guo, H., Hao, X., Wang, Q., Huang, J., He, N., Yu, H., Lin, X., Wei, S.,
1004 Wu, T., 2020. Association of Public Health Interventions with the Epidemiology of the COVID-
1005 19 Outbreak in Wuhan, China. *JAMA - J. Am. Med. Assoc.* 323, 1915–1923.
1006 <https://doi.org/10.1001/jama.2020.6130>
- 1007 Peccia, J., Zulli, A., Brackney, D.E., Grubaugh, N.D., Kaplan, E.H., Casanovas-Massana, A., Ko,
1008 A.I., Malik, A.A., Wang, D., Wang, M., Warren, J.L., Weinberger, D.M., Arnold, W., Omer,
1009 S.B., 2020. Measurement of SARS-CoV-2 RNA in wastewater tracks community infection
1010 dynamics. *Nat. Biotechnol.* 38, 1164–1167. <https://doi.org/10.1038/s41587-020-0684-z>
- 1011 Peterson, S.W., Lidder, R., Daigle, J., Wonitowy, Q., Dueck, C., Nagasawa, A., Mulvey, M.R.,

- 1012 Mangat, C.S., 2021. RT-qPCR detection of SARS-CoV-2 mutations S 69–70 del, S N501Y
1013 and N D3L associated with variants of concern in Canadian wastewater samples. *Sci. Total*
1014 *Environ.* 151283. <https://doi.org/10.1016/j.scitotenv.2021.151283>
- 1015 Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M., Planchais,
1016 C., Porrot, F., Robillard, N., Puech, J., Prot, M., Gallais, F., Gantner, P., Velay, A., Le Guen,
1017 J., Kassis-Chikhani, N., Edriss, D., Belec, L., Seve, A., Courtellemont, L., Péré, H.,
1018 Hocqueloux, L., Fafi-Kremer, S., Prazuck, T., Mouquet, H., Bruel, T., Simon-Lorière, E., Rey,
1019 F.A., Schwartz, O., 2021. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody
1020 neutralization. *Nature* 596, 276–280. <https://doi.org/10.1038/s41586-021-03777-9>
- 1021 Pouwels, K.B., House, T., Pritchard, E., Robotham, J. V., Birrell, P.J., Gelman, A., Vihta, K.D.,
1022 Bowers, N., Boreham, I., Thomas, H., Lewis, J., Bell, I., Bell, J.I., Newton, J.N., Farrar, J.,
1023 Diamond, I., Benton, P., Walker, Ann Sarah, Pouwels, K.B., Walker, A. Sarah, Crook, D.,
1024 Matthews, P.C., Peto, T., Stoesser, N., Howarth, A., Doherty, G., Kavanagh, J., Chau, K.K.,
1025 Hatch, S.B., Ebner, D., Martins Ferreira, L., Christott, T., Marsden, B.D., Dejnirattisai, W.,
1026 Mongkolsapaya, J., Hoosdally, S., Cornall, R., Stuart, D.I., Sreaton, G., Eyre, D., Bell, J.,
1027 Cox, S., Paddon, K., James, T., Newton, J.N., Robotham, J. V., Birrell, P., Jordan, H.,
1028 Sheppard, T., Athey, G., Moody, D., Curry, L., Brereton, P., Hay, J., Vansteenhout, H.,
1029 Lambert, A., Rourke, E., Hawkes, S., Henry, S., Scruton, J., Stokes, P., Thomas, T., Allen,
1030 J., Black, R., Bovill, H., Brauholtz, D., Brown, D., Collyer, S., Crees, M., Daghish, C., Davies,
1031 B., Donnarumma, H., Douglas-Mann, J., Felton, A., Finselbach, H., Fordham, E., Ipser, A.,
1032 Jenkins, J., Jones, J., Kent, K., Kerai, G., Lloyd, L., Masding, V., Osborn, E., Patel, A.,
1033 Pereira, E., Pett, T., Randall, M., Reeve, D., Shah, P., Snook, R., Studley, R., Sutherland,
1034 E., Swinn, E., Tudor, A., Weston, J., Leib, S., Tierney, J., Farkas, G., Cobb, R., Van Galen,
1035 F., Compton, L., Irving, J., Clarke, J., Mullis, R., Ireland, L., Airimitoiaie, D., Nash, C., Cox,

- 1036 D., Fisher, S., Moore, Z., McLean, J., Kerby, M., 2021. Community prevalence of SARS-
1037 CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection
1038 Survey. *Lancet Public Heal.* 6, e30–e38. [https://doi.org/10.1016/S2468-2667\(20\)30282-6](https://doi.org/10.1016/S2468-2667(20)30282-6)
- 1039 Public Health Ontario, 2021. Ontario COVID-19 Data Tool | Public Health Ontario [WWW
1040 Document]. *Public Heal. Ontario*. URL [https://www.publichealthontario.ca/en/data-and-](https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/covid-19-data-surveillance/covid-19-data-tool?tab=vaccine)
1041 [analysis/infectious-disease/covid-19-data-surveillance/covid-19-data-tool?tab=vaccine](https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/covid-19-data-surveillance/covid-19-data-tool?tab=vaccine)
1042 (accessed 9.28.21).
- 1043 Qiu, Y., Yu, J., Pabbaraju, K., Lee, B.E., Gao, T., Ashbolt, N.J., Hrudehy, S.E., Diggle, M., Tipples,
1044 G., Maal-Bared, R., Pang, X., 2021. Validating and optimizing the method for molecular
1045 detection and quantification of SARS-CoV-2 in wastewater. *Sci. Total Environ.* 812, 151434.
1046 <https://doi.org/10.1016/j.scitotenv.2021.151434>
- 1047 Quilliam, R.S., Weidmann, M., Moresco, V., Purshouse, H., O'Hara, Z., Oliver, D.M., 2020.
1048 COVID-19: The environmental implications of shedding SARS-CoV-2 in human faeces.
1049 *Environ. Int.* 140, 105790. <https://doi.org/10.1016/j.envint.2020.105790>
- 1050 Randazzo, W., Truchado, P., Cuevas-Ferrando, E., Simón, P., Allende, A., Sánchez, G., 2020.
1051 SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area.
1052 *Water Res.* 181. <https://doi.org/10.1016/j.watres.2020.115942>
- 1053 Rivett, L., Sridhar, S., Sparkes, D., Routledge, M., Jones, N.K., Forrest, S., Young, J., Pereira-
1054 Dias, J., Hamilton, W.L., Ferris, M., Torok, M.E., Meredith, L., Curran, M.D., Fuller, S.,
1055 Chaudhry, A., Shaw, A., Samworth, R.J., Bradley, J.R., Dougan, G., Smith, K.G.C., Lehner,
1056 P.J., Matheson, N.J., Wright, G., Goodfellow, I.G., Baker, S., Weekes, M.P., Lyons, P.A.,
1057 Toshner, M., Warne, B., Scott, J.B., Cormie, C., Gill, H., Kean, I., Maes, M., Reynolds, N.,
1058 Wantoch, M., Caddy, S., Caller, L., Feltwell, T., Hall, G., Hosmillo, M., Houldcroft, C., Jahun,

- 1059 A., Khokhar, F., Yakovleva, A., Butcher, H., Caputo, D., Clapham-Riley, D., Dolling, H.,
1060 Furlong, A., Graves, B., Gresley, E. Le, Kingston, N., Papadia, S., Stark, H., Stirrups, K.E.,
1061 Webster, J., Calder, J., Harris, J., Hewitt, S., Kennet, J., Meadows, A., Rastall, R., Brien,
1062 C.O., Price, J., Publico, C., Rowlands, J., Ruffolo, V., Tordesillas, H., Brookes, K., Canna,
1063 L., Cruz, I., Dempsey, K., Elmer, A., Escoffery, N., Jones, H., Ribeiro, C., Saunders, C.,
1064 Wright, A., Nyagumbo, R., Roberts, A., Bucke, A., Hargreaves, S., Johnson, D., Narcorda,
1065 A., Read, D., Sparke, C., Warboys, L., Lagadu, K., Mactavous, L., Gould, T., Raine, T.,
1066 Mather, C., Ramenatte, N., Vallier, A.L., Ksanicki, M., Eames, P.J., McNicholas, C., Thake,
1067 L., Bartholomew, N., Brown, N., Parmar, S., Zhang, H., Bowring, A., Martell, G., Quinell, N.,
1068 Wright, J., Murphy, H., Dunmore, B.J., Legchenko, E., Gräf, S., Huang, C., Hodgson, J.,
1069 Hunter, K., Martin, J., Mescia, F., O'donnell, C., Pointon, L., Shih, J., Sutcliffe, R., Tilly, T.,
1070 Tong, Z., Treacy, C., Wood, J., Bergamaschi, L., Betancourt, A., Bowyer, G., Sa, A. De,
1071 Epping, M., Hinch, A., Huhn, O., Jarvis, I., Lewis, D., Marsden, J., McCallum, S., Nice, F.,
1072 2020. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic
1073 carriage in COVID-19 transmission. *Elife* 9, 1–20. <https://doi.org/10.7554/eLife.58728>
- 1074 Rosenke, K., Feldmann, F., Okumura, A., Hansen, F., Tang-Huau, T., Meade-White, K., Kaza, B.,
1075 Smith, B.J., Hanley, P.W., Lovaglio, J., Jarvis, M.A., Shaia, C., Feldmann, H., 2021. UK
1076 B.1.1.7 variant exhibits increased respiratory replication and shedding in nonhuman primates.
1077 *bioRxiv* 2021.06.11.448134.
- 1078 Rubin, R., 2020. First It Was Masks; Now Some Refuse Testing for SARS-CoV-2. *JAMA - J. Am.*
1079 *Med. Assoc.* 324, 2015–2016. <https://doi.org/10.1001/jama.2020.22003>
- 1080 Santos, V.S., Gurgel, R.Q., Cuevas, L.E., Martins-Filho, P.R., 2020. Prolonged Fecal Shedding
1081 of SARS-CoV-2 in Pediatric Patients: A Quantitative Evidence Synthesis. *J. Pediatr.*
1082 *Gastroenterol. Nutr.* 71, 150–152. <https://doi.org/10.1097/MPG.0000000000002798>

- 1083 Shao, Ying, Shao, Yang, Fei, J.M., 2020. Psychiatry hospital management facing COVID-19:
1084 From medical staff to patients. *Brain. Behav. Immun.* 88, 947.
1085 <https://doi.org/10.1016/j.bbi.2020.04.018>
- 1086 Sherchan, S.P., Shahin, S., Ward, L.M., Tandukar, S., Aw, T.G., Schmitz, B., Ahmed, W., Kitajima,
1087 M., 2020. First detection of SARS-CoV-2 RNA in wastewater in North America: A study in
1088 Louisiana, USA. *Sci. Total Environ.* 743, 140621.
1089 <https://doi.org/10.1016/j.scitotenv.2020.140621>
- 1090 Shuai, H., Chan, J.F.-W., Hu, B., Chai, Y., Yuen, T.T.-T., Yin, F., Huang, X., Yoon, C., Hu, J.-C.,
1091 Liu, H., Shi, J., Liu, Y., Zhu, T., Zhang, J., Hou, Y., Wang, Y., Lu, L., Cai, J.-P., Zhang, A.J.,
1092 Zhou, J., Yuan, S., Brindley, M.A., Zhang, B.-Z., Huang, J.-D., To, K.K.-W., Yuen, K.-Y., Chu,
1093 H., 2022. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.
1094 *Nature.* <https://doi.org/10.1038/s41586-022-04442-5>
- 1095 Uhteg, K., Jarrett, J., Richards, M., Howard, C., Morehead, E., Geahr, M., Gluck, L., Hanlon, A.,
1096 Ellis, B., Kaur, H., Simner, P., Carroll, K.C., Mostafa, H.H., 2020. Comparing the analytical
1097 performance of three SARS-CoV-2 molecular diagnostic assays. *J. Clin. Virol.* 127, 104384.
1098 <https://doi.org/10.1016/j.jcv.2020.104384>
- 1099 Uscinski, J.E., Enders, A.M., Klofstad, C., Seelig, M., Funchion, J., Everett, C., Murthi, M., 2020.
1100 Why do people believe COVID-19 conspiracy theories? Research questions. *Harvard*
1101 *Kennedy Sch. Misinformation Rev.* 1, 1–12.
- 1102 Wade, M.J., Lo Jacomo, A., Armenise, E., Brown, M.R., Bunce, J.T., Cameron, G.J., Fang, Z.,
1103 Farkas, K., Gilpin, D.F., Graham, D.W., Grimsley, J.M.S., Hart, A., Hoffmann, T., Jackson,
1104 K.J., Jones, D.L., Lilley, C.J., McGrath, J.W., McKinley, J.M., McSparron, C., Nejad, B.F.,
1105 Morvan, M., Quintela-Baluja, M., Roberts, A.M.I., Singer, A.C., Souque, C., Speight, V.L.,

- 1106 Sweetapple, C., Walker, D., Watts, G., Weightman, A., Kasprzyk-Hordern, B., 2022.
1107 Understanding and managing uncertainty and variability for wastewater monitoring beyond
1108 the pandemic: Lessons learned from the United Kingdom national COVID-19 surveillance
1109 programmes. *J. Hazard. Mater.* 424. <https://doi.org/10.1016/j.jhazmat.2021.127456>
- 1110 Wikramaratna, P.S., Paton, R.S., Ghafari, M., Lourenço, J., 2020. Estimating the false-negative
1111 test probability of SARS-CoV-2 by RT-PCR. *Eurosurveillance* 25, 1–10.
1112 <https://doi.org/10.2807/1560-7917.ES.2020.25.50.2000568>
- 1113 World Health Organization, 2021. WHO Coronavirus Disease (COVID-19) Dashboard With
1114 Vaccination Data | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [WWW
1115 Document]. World Heal. Organ. URL
1116 <https://covid19.who.int/><https://covid19.who.int/region/searo/country/bd> (accessed
1117 3.22.22).
- 1118 Wu, F., Zhang, J., Xiao, A., Gu, X., Lee, W.L., Armas, F., Kauffman, K., Hanage, W., Matus, M.,
1119 Ghaeli, N., Endo, N., Duvallet, C., Poyet, M., Moniz, K., Washburne, A.D., Erickson, T.B.,
1120 Chai, P.R., Thompson, J., Alm, E.J., 2020. SARS-CoV-2 titers in wastewater are higher than
1121 expected from clinically confirmed cases. *mSystems* 5, 2020.04.05.20051540.
1122 <https://doi.org/10.1128/mSystems.00614-20>
- 1123 Xiao, A., Wu, F., Bushman, M., Zhang, J., Imakaev, M., Chai, P.R., Duvallet, C., Endo, N.,
1124 Erickson, T.B., Armas, F., Arnold, B., Chen, H., Chandra, F., Ghaeli, N., Gu, X., Hanage,
1125 W.P., Lee, W.L., Matus, M., McElroy, K.A., Moniz, K., Rhode, S.F., Thompson, J., Alm, E.J.,
1126 2022. Metrics to relate COVID-19 wastewater data to clinical testing dynamics. *Water Res.*
1127 212, 118070. <https://doi.org/10.1016/j.watres.2022.118070>
- 1128 Xu, Y., Li, X., Zhu, B., Liang, H., Fang, C., Gong, Y., Guo, Q., Sun, X., Zhao, D., Shen, J., Zhang,

- 1129 H., Liu, H., Xia, H., Tang, J., Zhang, K., Gong, S., 2020. Characteristics of pediatric SARS-
1130 CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat. Med.* 26, 502–
1131 505. <https://doi.org/10.1038/s41591-020-0817-4>
- 1132 Yadav, P.D., Sapkal, G.N., Abraham, P., Ella, R., Deshpande, G., Patil, D.Y., Nyayanit, D.A.,
1133 Gupta, N., Sahay, R.R., Shete, A.M., Panda, S., Bhargava, B., Mohan, V.K., 2021.
1134 Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees. *Clin.*
1135 *Infect. Dis.* 20, 547–558. <https://doi.org/10.1093/cid/ciab411>
- 1136 Yaniv, K., Ozer, E., Shagan, M., Lakkakula, S., Plotkin, N., Bhandarkar, N.S., Kushmaro, A., 2021.
1137 Direct RT-qPCR assay for SARS-CoV-2 variants of concern (Alpha, B.1.1.7 and Beta,
1138 B.1.351) detection and quantification in wastewater. *Environ. Res.* 201.
1139 <https://doi.org/10.1016/j.envres.2021.111653>
- 1140 Zhang, X., Wu, S., Wu, B., Yang, Q., Chen, A., Li, Y., Zhang, Y., Pan, T., Zhang, H., He, X., 2021.
1141 SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral
1142 entrance. *Signal Transduct. Target. Ther.* 6, 10–12. [https://doi.org/10.1038/s41392-021-](https://doi.org/10.1038/s41392-021-00852-5)
1143 [00852-5](https://doi.org/10.1038/s41392-021-00852-5)
- 1144 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu,
1145 P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G.F., Tan, W., 2020. A Novel
1146 Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl. J. Med.* 382, 727–733.
1147 <https://doi.org/10.1056/nejmoa2001017>
- 1148 Zhu, Y., Oishi, W., Maruo, C., Saito, M., Chen, R., Kitajima, M., Sano, D., 2021. Early warning of
1149 COVID-19 via wastewater-based epidemiology: potential and bottlenecks. *Sci. Total Environ.*
1150 767, 145124. <https://doi.org/10.1016/j.scitotenv.2021.145124>

1151 Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J.,
1152 Guo, Q., Song, T., He, J., Yen, H.-L., Peiris, M., Wu, J., 2020. SARS-CoV-2 Viral Load in
1153 Upper Respiratory Specimens of Infected Patients. N. Engl. J. Med. 382, 1177–1179.
1154 <https://doi.org/10.1056/NEJMc2001737>

1155